PARK7-Related Early-Onset Parkinson Disease

Mendelian MONDO:0011658 Pathograph 11 Show in embeddings browser Neurodegenerative Disease Movement Disorder Autosomal Recessive Early-Onset Parkinsonism

PARK7-related early-onset Parkinson disease (PARK-DJ1, autosomal recessive early-onset Parkinson disease 7) is a rare monogenic parkinsonism caused by biallelic loss-of-function variants in PARK7, which encodes DJ-1. DJ-1 is a small, ubiquitously expressed, homodimeric protein whose conserved cysteine at position 106 (Cys106) is progressively oxidized (Cys-SOH to Cys-SO2H to Cys-SO3H), making it a redox sensor and cytoprotective effector: oxidized DJ-1 relocalizes to the outer mitochondrial membrane, stabilizes the antioxidant master regulator NRF2 by preventing KEAP1-mediated ubiquitination, and acts as a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregation. DJ-1 also carries a glutathione-independent catalytic activity toward the reactive dicarbonyl methylglyoxal, though whether this constitutes a glyoxalase (free methylglyoxal to lactate) or a protein deglycase (repair of glycated residues) activity remains an active and unresolved controversy. Biallelic loss of DJ-1 removes this multi-pronged cytoprotective buffer, leaving substantia nigra pars compacta dopaminergic neurons - already burdened by high bioenergetic demand and dopamine-derived oxidant load - vulnerable to oxidative and dicarbonyl stress and mitochondrial dysfunction. The result is nigrostriatal dopaminergic degeneration, striatal dopamine deficiency, and levodopa-responsive parkinsonism with onset typically in the third decade, often accompanied by dystonia, early dyskinesia, and a high burden of psychiatric and cognitive non-motor features. PARK7 is the rarest of the three classic autosomal recessive early-onset Parkinson disease genes, accounting for roughly 0.4% of early-onset cases in a systematic review.

Ask OpenScientist

Ask a research question about PARK7-Related Early-Onset Parkinson Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
12
Phenotypes
3
Hypotheses
3
Gaps
11
Pathograph
1
Genes
3
Medical Actions
3
References
🏷

Classifications

Harrison's Part
NEUROLOGIC GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Disease requires biallelic PARK7 loss-of-function variants - homozygous (frequently in the setting of parental consanguinity or a founder haplotype) or compound heterozygous. Heterozygous carriers are generally unaffected, although heterozygous variants in the recessive PD genes have been reported in association with increased late-onset PD risk. The autosomal recessive mode is asserted independently by ClinGen's gene curation expert panel and by the founding genetic report.
Autosomal recessive inheritance
Show evidence (3 references)
PMID:12446870 SUPPORT Human Clinical
"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism."
The founding report titles the entity as autosomal recessive early-onset parkinsonism.
CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z SUPPORT Other
"PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
ClinGen records the mode of inheritance for the PARK7-Parkinson disease relationship as AR (autosomal recessive).
PMID:19694908 SUPPORT Other
"Recessively inherited loss-of-function mutations in the parkin, DJ-1, or PINK1 gene are linked to familial cases of early-onset Parkinson's diseases (PD), and heterozygous mutations are associated with increased incidence of late-onset PD."
Supports both the recessive mode and the reported heterozygote late-onset risk association. Marked PARTIAL because the heterozygote claim is a background statement, not a result of the cited study, and it pools the three recessive genes.
◈

Mechanistic Hypotheses

3
Canonical DJ-1 Redox-Sensor and Cytoprotection Model
dj1_oxidative_stress_cytoprotection_model CANONICAL
Evidence balance 1 support
The widely accepted model: DJ-1 is an oxidative-stress sensor whose conserved Cys106 is oxidized to cysteine-sulfinic acid under oxidant stress, which signals mitochondrial relocalization and cytoprotection; DJ-1 additionally stabilizes NRF2 (blocking KEAP1-mediated ubiquitination) to sustain antioxidant transcription, and acts as a redox-dependent chaperone limiting alpha-synuclein aggregation. Biallelic loss of DJ-1 removes this buffer, producing oxidative stress and mitochondrial dysfunction in nigral dopaminergic neurons. This model is the basis for the trigger-to-effector chain curated in this entry and is not seriously disputed at the level of "DJ-1 is cytoprotective under oxidative stress" - the disputes concern the biochemical mechanism (see the two dicarbonyl hypotheses below).
Show evidence (1 reference)
PMID:15181200 SUPPORT In Vitro
"We suggest that DJ-1 protects against neuronal death, and that this is signaled by acidification of the key cysteine residue, C106."
Establishes the Cys106-oxidation-signalled cytoprotection that anchors the canonical model.
DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification)
dj1_glyoxalase_dicarbonyl_detoxification ALTERNATIVE
Evidence balance 2 support
A competing biochemical account of DJ-1's catalytic activity: DJ-1 and its orthologs act as glutathione-independent glyoxalases that convert free glyoxal and methylglyoxal directly to glycolate and lactate, so that DJ-1 loss causes accumulation of reactive dicarbonyls and downstream glycation damage in dopaminergic neurons. This is supported by Michaelis-Menten kinetics on purified DJ-1, by protection of SH-SY5Y cells and C. elegans from glyoxal challenge, and by the observation that dopaminergic neurons degenerate in DJ-1-homolog-null worms exposed to sublethal glyoxal. Kinetic work reconciling the two dicarbonyl accounts (PMID:31653696) favours THIS activity as the real one and attributes the apparent deglycase activity to a rapid equilibrium artifact - but even that study found that DJ-1 loss did not protect human cells from acute methylglyoxal toxicity, and a Drosophila in vivo study found no contribution of DJ-1 to methylglyoxal detoxification at all. The relative contribution of dicarbonyl stress to human PARK-DJ1 neurodegeneration is therefore NOT settled.
Pathograph links
Biallelic PARK7 Loss of Function -> Loss of DJ-1 Dicarbonyl Detoxification Capacity DIRECT Under either dicarbonyl hypothesis, absence of DJ-1 removes its catalytic activity toward methylglyoxal and glyoxal. This edge is deliberately assigned to BOTH contested dicarbonyl hypothesis groups rather than asserted as an established part of the canonical chain.
Loss of DJ-1 Dicarbonyl Detoxification Capacity -> Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons INDIRECT UNKNOWN INTERMEDIATES Under either dicarbonyl hypothesis, accumulating methylglyoxal and protein glycation would add to the carbonyl and oxidant burden on nigral dopaminergic neurons. Modelled as indirect and hypothesis-scoped because the in vivo contribution in human PARK-DJ1 is unestablished.
Show evidence (2 references)
PMID:22523093 SUPPORT In Vitro
"human DJ-1 and its homologs of the mouse and Caenorhabditis elegans are novel types of glyoxalase, converting glyoxal or methylglyoxal to glycolic or lactic acid, respectively, in the absence of glutathione"
The originating biochemical claim for the glutathione-independent glyoxalase hypothesis.
PMID:31653696 SUPPORT In Vitro
"We found that removal of free MGO by DJ-1's glyoxalase activity forces immediate spontaneous decomposition of hemithioacetals due to the shift in equilibrium position."
Kinetic analysis that adjudicates between the two dicarbonyl hypotheses in favour of glyoxalase activity, while explaining the deglycase observations as an equilibrium artifact. Marked PARTIAL because the same paper reports that DJ-1 knockout did not protect human cells from acute methylglyoxal toxicity, so it supports the enzymology without supporting a cellular protective role.
DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
dj1_protein_deglycase_repair ALTERNATIVE
Evidence balance 1 support 2 refute
The rival biochemical account: rather than scavenging free dicarbonyls, DJ-1 acts on early glycation intermediates already formed on proteins, deglycating cysteine, arginine and lysine residues and thereby reactivating damaged proteins, so that PARK-DJ1 parkinsonism would result from excessive protein glycation. This hypothesis has been directly and repeatedly challenged: a Drosophila in vivo study detected no contribution of DJ-1 to methylglyoxal-adduct accumulation or survival and attributed the reported deglycation activity to a TRIS buffer artifact, and an independent kinetic study concluded that DJ-1 does not possess protein deglycase activity, with the apparent activity arising from the fast equilibrium between free methylglyoxal and hemithioacetals. It is retained here as an explicitly contested ALTERNATIVE rather than removed, because it remains a live disagreement in the literature and because the deglycase framing continues to be cited in reviews.
Pathograph links
Biallelic PARK7 Loss of Function -> Loss of DJ-1 Dicarbonyl Detoxification Capacity DIRECT Under either dicarbonyl hypothesis, absence of DJ-1 removes its catalytic activity toward methylglyoxal and glyoxal. This edge is deliberately assigned to BOTH contested dicarbonyl hypothesis groups rather than asserted as an established part of the canonical chain.
Loss of DJ-1 Dicarbonyl Detoxification Capacity -> Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons INDIRECT UNKNOWN INTERMEDIATES Under either dicarbonyl hypothesis, accumulating methylglyoxal and protein glycation would add to the carbonyl and oxidant burden on nigral dopaminergic neurons. Modelled as indirect and hypothesis-scoped because the in vivo contribution in human PARK-DJ1 is unestablished.
Show evidence (3 references)
PMID:25416785 SUPPORT In Vitro
"we show that human DJ-1 is a protein deglycase that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins by acting on early glycation intermediates"
The originating claim for the protein-deglycase hypothesis.
PMID:27903648 REFUTE Model Organism
"Using both DJ-1 knockdown in Drosophila cells in culture, and DJ-1β knock-out flies, we could detect no contribution of DJ-1 to survival to MG challenge or to accumulation of MG protein adducts."
In vivo Drosophila refutation of the deglycase/detoxification role, including attribution of the reported activity to a buffer artifact.
PMID:31653696 REFUTE In Vitro
"Combined, our results suggest that DJ-1 does not possess protein deglycase activity."
Independent kinetic refutation of the deglycase hypothesis.
?

Discussions and Knowledge Gaps

3
Why do DJ-1 knockout mice - and even parkin/DJ-1/PINK1 triple knockout mice aged to 24 months - fail to lose nigral dopaminergic neurons, when biallelic PARK7 loss reliably causes nigrostriatal degeneration in humans?
HUMAN MODEL MISMATCH OPEN park7_dj1_knockout_no_nigral_degeneration
Attached to
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
This is the textbook translational mismatch of the recessive Parkinson disease genes. DJ-1 null mice reproduce dopaminergic FUNCTIONAL deficits - markedly reduced evoked striatal dopamine overflow, loss of corticostriatal long-term depression, open-field hypoactivity - but the substantia nigra dopaminergic neuron count is normal. Removing all three recessive PD gene products together does not rescue the model: triple knockouts still have normal nigral and locus coeruleus neuron numbers at 3, 16 and 24 months. The mismatch is mechanistically meaningful because it means that no existing rodent genetic model tests the step this entry most needs - the transition from cellular oxidative/bioenergetic stress to actual dopaminergic neuron death - and because it admits at least three distinct interpretations that current data do not separate: (a) mouse lifespan is simply too short for a slowly cumulative oxidative injury to reach the degeneration threshold; (b) DJ-1 is protective/modulatory rather than strictly required for nigral neuron survival, with the human phenotype requiring an additional insult or cumulative exposome that mice do not experience; or (c) species differences in dopaminergic neuron oxidant burden, neuromelanin (absent in mouse nigra), and antioxidant redundancy mean the mouse nigra is simply not the vulnerable cell population the human nigra is. Compounding this, the human end of the comparison is almost unconstrained: only ONE PARK7 patient brain has ever been examined neuropathologically. Any conclusion drawn from a negative mouse result should therefore be treated as uninformative about human PARK-DJ1 rather than as evidence against the mechanism.
Proposed experiments
Multi-brain neuropathological characterisation of PARK7 mutation carriers
human post-mortem neuropathological case series Relation: this experiment is of type this experiment type This experiment is of type human post-mortem neuropathological case series.
exp_park7_multibrain_neuropathology
Coordinate international brain banks to obtain and systematically examine every available brain from a confirmed biallelic PARK7 carrier: stereological nigral dopaminergic cell counts, alpha-synuclein and Lewy body staging, and oxidative/carbonyl damage markers, benchmarked against age-matched idiopathic Parkinson disease and control brains. This is the only way to constrain the human end of the comparison, which currently rests on a single L172Q case.
Readouts
Nigral dopaminergic neuron loss
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Direction: POSITIVE
Decision criterion
Consistent stereological nigral dopaminergic cell loss across multiple PARK7 brains would confirm the human effector node and establish that the negative mouse result is a model limitation rather than evidence against the mechanism.
Would support
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Aged patient-derived iPSC midbrain dopaminergic neurons and organoids
patient-derived iPSC neuronal model experiment Relation: this experiment is of type this experiment type This experiment is of type patient-derived iPSC neuronal model experiment.
exp_park7_ipsc_dopaminergic_ageing
Differentiate midbrain dopaminergic neurons and midbrain organoids from PARK7 null and L166P patient iPSCs alongside isogenic corrected controls, age them in culture, and challenge with sub-threshold oxidative and dicarbonyl stressors. Measure survival, mitochondrial function, and reactive oxygen species to test whether HUMAN dopaminergic neurons - unlike mouse - degenerate on DJ-1 loss.
Perturbations
Oxidative and dicarbonyl challenge of DJ-1-null human dopaminergic neurons
pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
Sub-threshold paraquat/hydrogen peroxide and methylglyoxal exposure of PARK7-null versus isogenic-corrected human midbrain dopaminergic neurons.
Readouts
Dopaminergic neuron survival
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Direction: POSITIVE
Decision criterion
Selective death of PARK7-null human dopaminergic neurons under stress, rescued by isogenic correction, would show the stress-to-death step is human-permissive and mouse-refractory.
Would support
pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
Longitudinal dopaminergic imaging in PARK7 biallelic carriers
longitudinal neuroimaging cohort study Relation: this experiment is of type this experiment type This experiment is of type longitudinal neuroimaging cohort study.
exp_park7_longitudinal_dat_neuromelanin_imaging
Serial dopamine-transporter SPECT/PET and neuromelanin-sensitive MRI in biallelic PARK7 carriers versus matched idiopathic early-onset Parkinson disease, to quantify the in vivo human rate of nigrostriatal loss - the benchmark any animal or cellular model must reproduce.
Readouts
Rate of striatal dopamine transporter signal decline
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Direction: NEGATIVE
Decision criterion
A measurable, progressive decline in nigrostriatal imaging markers in PARK7 carriers establishes the in vivo human degeneration rate against which the null mouse phenotype can be judged.
Second-hit and long-lived-model designs in DJ-1 null animals
gene-environment interaction animal model experiment Relation: this experiment is of type this experiment type This experiment is of type gene-environment interaction animal model experiment.
exp_park7_second_hit_dj1_null_mice
Challenge DJ-1 null mice with sub-threshold oxidative or dicarbonyl stressors that do not cause degeneration in wild-type animals, and in parallel generate DJ-1 loss-of-function in a longer-lived or neuromelanin-bearing species, to discriminate the "mouse lifespan too short" interpretation from the "DJ-1 is protective but not required" interpretation.
Perturbations
Sub-threshold oxidative or dicarbonyl second hit
pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
Chronic low-dose paraquat, rotenone, or methylglyoxal exposure in DJ-1 null versus wild-type animals.
Decision criterion
Nigral degeneration emerging in DJ-1 null but not wild-type animals under a second hit would support the protective-not-required reading; degeneration emerging only with extended lifespan would support the lifespan reading.
Show evidence (4 references)
PMID:15721235 SUPPORT Model Organism
"Although DJ-1(-/-) mice had normal numbers of dopaminergic neurons in the substantia nigra, evoked dopamine overflow in the striatum was markedly reduced, primarily as a result of increased reuptake."
The canonical demonstration that DJ-1 null mice reproduce dopaminergic dysfunction without nigral cell loss.
PMID:19694908 SUPPORT Model Organism
"we found that triple knockout mice lacking Parkin, DJ-1, and PINK1 have normal morphology and numbers of dopaminergic and noradrenergic neurons in the substantia nigra and locus coeruleus, respectively, at the ages of 3, 16, and 24 months."
Shows that combined inactivation of all three recessive PD genes still fails to produce nigral degeneration within the mouse lifespan.
PMID:19694908 SUPPORT Model Organism
"suggesting that these genes may be protective rather than essential for the survival of dopaminergic neurons during the aging process"
The authors' own preferred interpretation, curated here as one of the competing readings of the mismatch.
+ 1 more reference
Is DJ-1's catalytic activity toward reactive dicarbonyls a glutathione-independent glyoxalase activity on free methylglyoxal, a protein deglycase activity repairing already-formed glycation adducts, or neither in vivo - and does dicarbonyl stress contribute materially to human PARK-DJ1 neurodegeneration?
CONTROVERSY OPEN park7_glyoxalase_versus_deglycase_controversy
Attached to
pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
This is a genuine, unresolved scientific disagreement, not a curation ambiguity, and it is curated as a controversy rather than asserted in either direction. The glyoxalase claim (DJ-1 converts free glyoxal and methylglyoxal to glycolate and lactate without glutathione) and the deglycase claim (DJ-1 repairs methylglyoxal- and glyoxal-glycated cysteine, arginine and lysine residues on proteins) were published as competing biochemical accounts of the same protein. The deglycase claim was then directly challenged twice: a Drosophila study detected no contribution of DJ-1 to methylglyoxal survival or adduct accumulation in vivo and ascribed the reported deglycation to a TRIS buffer artifact, prompting published rebuttal correspondence in the same journal; and an independent kinetic analysis showed that the fast equilibrium between free methylglyoxal and hemithioacetals (equilibrium constant ~500 per molar, hemithioacetal half-life 12 s) means that glyoxalase-mediated removal of free methylglyoxal forces spontaneous hemithioacetal decomposition that can be mistaken for deglycase activity. That second study concluded that DJ-1 does not possess protein deglycase activity - but ALSO found that DJ-1-knockout human cells were not sensitised to acute methylglyoxal toxicity, so it does not rescue the glyoxalase arm as a disease-relevant protective mechanism either. The practical consequence for this entry is that the dicarbonyl node and its downstream edge are scoped to hypothesis groups rather than folded into the canonical chain, and no PARK-DJ1 clinical or therapeutic claim is made on the basis of dicarbonyl biology.
Proposed experiments
Quantification of methylglyoxal-derived AGEs in PARK7 patient tissue
targeted mass spectrometry biomarker study Relation: this experiment is of type this experiment type This experiment is of type targeted mass spectrometry biomarker study.
exp_park7_human_age_quantification
Measure methylglyoxal-derived advanced glycation end-products (MG-H1, argpyrimidine, carboxyethyl-lysine) by mass spectrometry in substantia nigra tissue and CSF from biallelic PARK7 carriers versus idiopathic Parkinson disease and controls, to test whether dicarbonyl stress is actually elevated in the human disease rather than only in reconstituted systems.
Readouts
Methylglyoxal-derived advanced glycation end-product burden
pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
Direction: POSITIVE
Decision criterion
Elevated MG-derived AGEs in PARK7 nigra/CSF relative to controls would promote the dicarbonyl node from hypothesis-scoped to canonical; no elevation would justify demoting it.
Would support
pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
Separation-of-function DJ-1 alleles in human dopaminergic neurons
structure-guided separation-of-function rescue experiment Relation: this experiment is of type this experiment type This experiment is of type structure-guided separation-of-function rescue experiment.
exp_park7_separation_of_function_alleles
Design structure-guided DJ-1 alleles that ablate glyoxalase activity while preserving Cys106 redox sensing and NRF2 stabilisation, and conversely, and express each in PARK7-null patient-derived iPSC dopaminergic neurons to determine which activity is required for dopaminergic neuron survival under stress.
Perturbations
Activity-selective DJ-1 rescue alleles
pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
Re-expression of glyoxalase-dead but redox-competent DJ-1, and redox-dead but glyoxalase-competent DJ-1, in PARK7-null human dopaminergic neurons.
Decision criterion
If only the redox-competent allele rescues survival, the dicarbonyl arm is dispensable for the disease mechanism; if the glyoxalase-competent allele also rescues, dicarbonyl detoxification is disease-relevant.
Would refute
pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
Multi-laboratory buffer-controlled replication of DJ-1 enzyme kinetics
multi-laboratory enzyme kinetics replication study Relation: this experiment is of type this experiment type This experiment is of type multi-laboratory enzyme kinetics replication study.
exp_park7_buffer_controlled_kinetics_replication
Standardised, TRIS-free, buffer-controlled re-measurement of DJ-1 glyoxalase and deglycase kinetics across independent laboratories using shared protein preparations and substrates, since a buffer artifact is one of the explicit competing explanations for the discrepant results.
Decision criterion
Reproducible deglycase activity under TRIS-free conditions across laboratories would restore the deglycase hypothesis; its absence would settle the controversy in favour of glyoxalase-only activity.
Show evidence (4 references)
PMID:22523093 SUPPORT In Vitro
"Purified DJ-1 proteins exhibit typical Michaelis-Menten kinetics, which were abolished completely in the mutants of essential catalytic residues, consisting of cysteine and glutamic acid."
Enzymological support for the glyoxalase side of the controversy.
PMID:25416785 SUPPORT In Vitro
"These results suggest that DJ-1-associated Parkinsonism results from excessive protein glycation and establishes DJ-1 as a major anti-glycation and anti-aging protein."
The deglycase side of the controversy, stated as an explicit pathogenic model for PARK-DJ1.
PMID:27903648 REFUTE Model Organism
"we could detect no contribution of DJ-1 to survival to MG challenge or to accumulation of MG protein adducts"
In vivo refutation of any DJ-1 contribution to methylglyoxal handling.
+ 1 more reference
Is PARK7-related early-onset Parkinson disease a synucleinopathy? Only a single mutation-carrier brain has been examined, and it showed Lewy body pathology.
KNOWLEDGE GAP OPEN park7_synucleinopathy_status_unknown
Attached to
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
The `Parkinson's Disease` entry models alpha-synuclein aggregation and Lewy pathology as a central mechanism, and the shared parkinsonism_dopaminergic_degeneration module carries an alpha-synuclein arm that conforming disorders may include or omit. This entry deliberately OMITS that arm, because the evidence to include it does not exist: exactly one DJ-1-mutation brain (L172Q) has been analysed neuropathologically. It did show Lewy bodies, which is suggestive but is a single observation. Cell-biological work independently shows that DJ-1 acts as a redox-dependent chaperone whose activity extends to alpha-synuclein, giving a plausible mechanistic route from DJ-1 loss to alpha-synuclein aggregation - but plausibility from in vitro chaperone assays plus one autopsy is not a basis for asserting a synucleinopathy node in the pathograph. Resolving this determines whether PARK-DJ1 should declare conformance to the module's alpha-synuclein node and whether synuclein-directed therapies are mechanistically rational here.
Proposed experiments
Systematic alpha-synuclein neuropathology survey of PARK7 brains
human post-mortem immunohistochemistry survey Relation: this experiment is of type this experiment type This experiment is of type human post-mortem immunohistochemistry survey.
exp_park7_synuclein_neuropathology_survey
Via international brain-bank coordination, apply alpha-synuclein immunohistochemistry, Lewy body staging, and oxidised-DJ-1 staining to every obtainable brain from a biallelic PARK7 carrier, to determine whether Lewy pathology is a consistent feature or an isolated finding in the single reported L172Q case.
Readouts
Alpha-synuclein Lewy pathology burden
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Direction: POSITIVE
Decision criterion
Consistent Lewy pathology across multiple PARK7 brains would justify adding an alpha-synuclein node and declaring conformance to the module's alpha-synuclein arm; its absence would confirm the current omission.
Alpha-synuclein seed amplification assay in living PARK7 carriers
seed amplification assay biomarker study Relation: this experiment is of type this experiment type This experiment is of type seed amplification assay biomarker study.
exp_park7_synuclein_seed_amplification
Perform alpha-synuclein seed amplification (RT-QuIC) on CSF and skin biopsy from living biallelic PARK7 carriers, which can establish synucleinopathy status in vivo without waiting for autopsy material and can be repeated longitudinally.
Readouts
CSF and skin alpha-synuclein seeding activity
pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
Direction: POSITIVE
Decision criterion
Positive seeding activity in a majority of PARK7 carriers would classify PARK-DJ1 as a synucleinopathy in vivo; consistently negative assays would establish it as a non-synuclein dopaminergic degeneration.
Show evidence (2 references)
PMID:31484320 SUPPORT Other
"very little is known regarding the neuropathology in brains from patients carrying DJ-1 mutations"
States the gap directly: the neuropathology of PARK-DJ1 is essentially uncharacterised.
PMID:15502874 SUPPORT INDIRECT In Vitro
"We further demonstrate that DJ-1 chaperone activity in vivo extends to alpha-synuclein, a protein implicated in PD pathogenesis."
Provides the mechanistic plausibility for a synuclein link. Marked INDIRECT because chaperone activity in a cellular system does not establish that human PARK-DJ1 brains accumulate alpha-synuclein.
⚙

Pathophysiology

7
Biallelic PARK7 Loss of Function
The initiating lesion is complete or near-complete loss of functional DJ-1 protein from biallelic PARK7 variants. Two mechanistic classes were identified in the founding families and remain representative: large genomic deletions removing the 5' portion of the gene (a 14,082 bp deletion segregating in a Dutch kindred), which abolish transcript production outright; and destabilising missense substitutions, prototyped by the homozygous L166P change in an Italian family. L166P sits in a C-terminal helix-kink-helix motif; helix-breaking substitutions there dramatically lower steady-state DJ-1 levels through accelerated degradation involving in part the proteasome, and abolish DJ-1 homodimerisation. Because DJ-1 is obligately dimeric for function, both classes converge on functional nullity.
DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification) DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
PARK7 hgnc:16369 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PARK7 (hgnc:16369). hgnc:16369 is a gene from the HUGO Gene Nomenclature Committee.
DJ-1 protein homodimerization GO:0042803 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DJ-1 protein homodimerization, annotated with protein homodimerization activity (GO:0042803). GO:0042803 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Loss of DJ-1 Cys106 Redox Sensing and Cytoprotection Absence of functional DJ-1 protein directly removes the Cys106 redox-sensing, mitochondrial-relocalisation, and chaperone functions.
Loss of DJ-1 Dicarbonyl Detoxification Capacity Under either dicarbonyl hypothesis, absence of DJ-1 removes its catalytic activity toward methylglyoxal and glyoxal. This edge is deliberately assigned to BOTH contested dicarbonyl hypothesis groups rather than asserted as an established part of the canonical chain. DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification) DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
Show evidence (4 references)
PMID:12446870 SUPPORT Human Clinical
"we show that DJ-1 mutations are associated with PARK7, a monogenic form of human parkinsonism."
The founding human genetic evidence establishing PARK7/DJ-1 as the causal gene of this entity.
PMID:12446870 SUPPORT Human Clinical
"Our findings indicate that loss of DJ-1 function leads to neurodegeneration."
States the loss-of-function direction of effect that makes this a trigger node rather than a gain-of-function lesion.
PMID:31484320 SUPPORT Other
"due to a deletion of 14,082 bp in a Dutch family or a homozygous point mutation (L166P) in an Italian family"
Documents the two representative variant classes (large deletion and destabilising missense) in the founding families.
+ 1 more reference
Loss of DJ-1 Cys106 Redox Sensing and Cytoprotection
In wild-type cells the conserved Cys106 of DJ-1 is the preferential target of oxidative modification, stepping through sulfenic (Cys-SOH), sulfinic (Cys-SO2H) and sulfonic (Cys-SO3H) states. Formation of cysteine-sulfinic acid at Cys106 is the switch that drives DJ-1 to the outer mitochondrial membrane and confers protection against the complex I inhibitor MPP+; an artificial C106A substitution abolishes both the pI shift and the protection, and behaves as a partial dominant negative. DJ-1 also functions as a redox-sensitive molecular chaperone activated in an oxidising cytoplasmic environment, with chaperone activity extending to alpha-synuclein. Loss of DJ-1 therefore removes an oxidant-triggered, self-amplifying cytoprotective response precisely when the cell most needs it. This node substitutes the module's generic toxic insult with a cell-intrinsic genetic one: the same dopaminergic vulnerability is reached by removing endogenous defence rather than by adding a poison.
Dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
cellular response to oxidative stress GO:0034599 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular response to oxidative stress (GO:0034599). GO:0034599 is a biological process from the Gene Ontology. ↓ DECREASED mitochondrion organization GO:0007005 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated mitochondrion organization (GO:0007005). GO:0007005 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Impaired NRF2 Antioxidant Transcriptional Response Without DJ-1, NRF2 is not shielded from KEAP1 and the antioxidant transcriptional programme it drives collapses.
Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons Loss of the Cys106-triggered mitochondrial cytoprotective response leaves dopaminergic neurons exposed to oxidant and bioenergetic injury.
Show evidence (4 references)
PMID:15181200 SUPPORT In Vitro
"oxidation-induced mitochondrial relocalization of DJ-1 and protection against cell death were abrogated in C106A but not C53A or C46A."
Demonstrates that Cys106 specifically is required for the oxidation-triggered mitochondrial relocalisation and cytoprotection lost in DJ-1 deficiency.
PMID:31484320 SUPPORT Other
"Cys106 is the preferential target for oxidative protein modification and is required for DJ-1 mediated protection from oxidative stress"
Review-level confirmation that Cys106 is the redox-sensing residue required for DJ-1's protective function.
PMID:15502874 SUPPORT In Vitro
"Here we show that DJ-1 functions as a redox-sensitive molecular chaperone that is activated in an oxidative cytoplasmic environment."
Establishes the redox-dependent chaperone arm of DJ-1 function, whose loss is part of this node.
+ 1 more reference
Loss of DJ-1 Dicarbonyl Detoxification Capacity
DJ-1 carries a glutathione-independent catalytic activity toward the reactive dicarbonyls methylglyoxal and glyoxal, byproducts of glycolysis that non-enzymatically glycate cysteine, arginine and lysine residues. The nature of that activity is genuinely disputed: one account has DJ-1 scavenging free dicarbonyl (glyoxalase III activity, converting methylglyoxal to lactate), while the other has it repairing already-formed glycation adducts on proteins (protein deglycase activity). Kinetic work favours the glyoxalase account and explains the deglycase observations as an artifact of the fast equilibrium between free methylglyoxal and hemithioacetals; in vivo Drosophila data question whether either activity matters for dicarbonyl handling at all. This node is therefore modelled as a hypothesis-scoped amplifier rather than an established step: it is included because the biochemistry is real and disease-relevant, and it is tagged to its competing hypothesis groups so downstream tooling does not read it as settled.
DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification) DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
Dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
methylglyoxal catabolic process GO:0051596 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased methylglyoxal catabolic process (GO:0051596). GO:0051596 is a biological process from the Gene Ontology. ↓ DECREASED
glyoxalase III activity (glutathione-independent) GO:0019172 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased glyoxalase III activity (glutathione-independent), annotated with glyoxalase III activity (GO:0019172). GO:0019172 is a molecular function from the Gene Ontology. ↓ DECREASED protein deglycase activity (contested) GO:0036524 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased protein deglycase activity (contested), annotated with protein deglycase activity (GO:0036524). GO:0036524 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons Under either dicarbonyl hypothesis, accumulating methylglyoxal and protein glycation would add to the carbonyl and oxidant burden on nigral dopaminergic neurons. Modelled as indirect and hypothesis-scoped because the in vivo contribution in human PARK-DJ1 is unestablished. DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification) DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
Show evidence (2 references)
PMID:22523093 SUPPORT Model Organism
"Sub-lethal doses of glyoxals caused significant degeneration of the dopaminergic neurons in C. elegans lacking cDJR-1.2, another DJ-1 homolog expressed primarily in the head region, including neurons."
Model-organism evidence tying loss of a DJ-1 homolog plus dicarbonyl exposure specifically to dopaminergic neuron degeneration. Kept as supporting evidence for the hypothesis-scoped node, not for the canonical human chain.
PMID:27903648 REFUTE Model Organism
"Furthermore, we provide data suggesting that the previously reported deglycation activity of DJ-1 can be ascribed to a TRIS buffer artifact."
Explicit refutation retained on the node so the controversy is visible in the pathograph rather than buried in prose.
Impaired NRF2 Antioxidant Transcriptional Response
DJ-1 stabilises NFE2L2 (NRF2), the master transcriptional regulator of the cellular antioxidant response, by preventing its association with the inhibitor KEAP1 and its subsequent ubiquitination. In the absence of intact DJ-1, NRF2 protein is unstable and antioxidant transcriptional responses fall both basally and after induction, with measurable deficits in the detoxification enzyme NQO1 and, in the wider DJ-1/NRF2 literature, in glutathione peroxidase, superoxide dismutase and heme oxygenase-1. This converts an acute, recoverable oxidant insult into a chronic inability to mount an antioxidant defence.
Dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
NRF2 protein stabilization by DJ-1 GO:0050821 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased NRF2 protein stabilization by DJ-1, annotated with protein stabilization (GO:0050821). GO:0050821 is a biological process from the Gene Ontology. ↓ DECREASED reactive oxygen species metabolic process GO:0072593 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated reactive oxygen species metabolic process (GO:0072593). GO:0072593 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons Failure of NRF2-driven antioxidant transcription leaves reactive oxygen species unbuffered in dopaminergic neurons.
Show evidence (3 references)
PMID:17015834 SUPPORT In Vitro
"DJ-1 stabilizes Nrf2 by preventing association with its inhibitor protein, Keap1, and Nrf2's subsequent ubiquitination."
Defines the molecular mechanism of the DJ-1/NRF2 axis lost in DJ-1 deficiency.
PMID:17015834 SUPPORT In Vitro
"Without intact DJ-1, Nrf2 protein is unstable, and transcriptional responses are thereby decreased both basally and after induction."
States the loss-of-function consequence that this node models.
PMID:40159591 SUPPORT Other
"In the DJ-1 or Nrf2 axis, expression of key antioxidant enzymes (glutathione peroxidase (GPx), superoxide dismutase (SOD), and heme oxygenase-1 (HO-1) in response to oxidative stress is increased, and decreased neuronal damage resulting from oxidative stress is achieved."
Identifies the downstream antioxidant enzymes whose induction depends on an intact DJ-1/NRF2 axis.
Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
The convergent cellular lesion is unbuffered oxidative stress with mitochondrial dysfunction in substantia nigra pars compacta dopaminergic neurons. This is the same convergence node the shared parkinsonism_dopaminergic_degeneration module places downstream of environmental complex I toxins (MPTP, rotenone, paraquat) - PARK7 loss reaches it from the opposite direction, by removing endogenous antioxidant defence rather than by adding an exogenous poison. Substantia nigra dopaminergic neurons are selectively vulnerable because of their high bioenergetic demand and high basal reactive oxygen species load; DJ-1 is normally most highly expressed exactly in such high-energy-demand, high-ROS cells. Consistent with the human relevance of this node, oxidised DJ-1 accumulates in the substantia nigra of ageing and idiopathic Parkinson disease brains.
Dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED mitochondrion organization GO:0007005 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated mitochondrion organization (GO:0007005). GO:0007005 is a biological process from the Gene Ontology. ↕ DYSREGULATED
substantia nigra pars compacta UBERON:0002038 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in substantia nigra pars compacta, annotated with substantia nigra (UBERON:0002038). UBERON:0002038 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Nigrostriatal Dopaminergic Neurodegeneration Chronic oxidative and bioenergetic stress in a selectively vulnerable neuronal population drives its progressive degeneration. Marked indirect because the proximate death mechanism in human PARK-DJ1 nigral neurons has not been established (see the human/model mismatch discussion).
Show evidence (3 references)
PMID:40159591 SUPPORT Other
"Oxidized DJ-1 (OxiDJ-1) is generated in aging brains, particularly in the substantia nigra (SN), and is correlated with PD progression"
Anchors the oxidative-stress node to the human substantia nigra rather than to cell culture alone.
PMID:31484320 SUPPORT Other
"DJ-1 is highly expressed in cells with high energy demands, hence cells with higher levels of reactive oxygen species."
Explains why loss of DJ-1 preferentially unmasks injury in high-bioenergetic-demand, high-ROS cells such as nigral dopaminergic neurons.
PMID:12446870 SUPPORT Human Clinical
"The function of the DJ-1 protein remains unknown, but evidence suggests its involvement in the oxidative stress response."
The founding report already placed DJ-1 in the oxidative stress response. Marked PARTIAL because it flags the function as then-unknown and does not itself demonstrate nigral oxidative injury.
Nigrostriatal Dopaminergic Neurodegeneration
Progressive loss of substantia nigra pars compacta dopaminergic neurons and their nigrostriatal projection - the shared effector lesion of all dopaminergic parkinsonisms. In PARK-DJ1 this is inferred clinically and from dopaminergic imaging rather than from neuropathology: only a single brain from a patient with a DJ-1 mutation (L172Q) has ever been analysed, and it showed Lewy body pathology, so whether PARK-DJ1 is routinely a synucleinopathy is unknown. Rodent models are explicitly discordant here: DJ-1 knockout mice, and even parkin/DJ-1/PINK1 triple knockout mice up to 24 months, retain normal numbers of nigral dopaminergic neurons while showing dopaminergic functional deficits - a human/model mismatch curated as a discussion below.
Dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
neuron apoptotic process GO:0051402 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neuron apoptotic process (GO:0051402). GO:0051402 is a biological process from the Gene Ontology. ↑ INCREASED
substantia nigra pars compacta UBERON:0002038 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in substantia nigra pars compacta, annotated with substantia nigra (UBERON:0002038). UBERON:0002038 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction Loss of the nigrostriatal projection depletes striatal dopamine.
Show evidence (2 references)
PMID:19694908 SUPPORT Other
"each of which was required for nigral neuron survival in the aging human brain"
States the premise underlying this node: DJ-1 (alongside parkin and PINK1) is required for nigral neuron survival in the ageing human brain. Tagged OTHER because the quoted clause is the authors' framing of the human genetics, not a result of their mouse experiment.
PMID:31484320 SUPPORT Human Clinical
"has been analyzed thus far, which notably exhibited Lewy body (LB) pathology"
The only direct human neuropathological observation in PARK-DJ1 (the quoted clause refers to the single analysed DJ-1 L172Q brain). Marked PARTIAL because a single autopsy cannot establish the general neuropathology of the entity.
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
Depletion of striatal dopamine unbalances the basal ganglia thalamocortical motor circuit and produces the cardinal parkinsonian signs - bradykinesia, rigidity, and tremor - with prominent dystonia in this early-onset recessive form. Because the deficit is a dopamine deficiency in an otherwise responsive circuit, PARK-DJ1 parkinsonism is characteristically and durably levodopa-responsive, which is also the mechanistic rationale for dopamine replacement therapy. The same circuit deficit, chronically over-stimulated by pulsatile levodopa, underlies the relatively early motor complications (dyskinesia) reported in this and the other recessive early-onset forms. Scale note: tagged TISSUE because the node's substrate is the striatum and the basal ganglia thalamocortical circuit; the organism-level motor syndrome it produces is captured in `phenotypes` rather than bundled into this node.
Striatal medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Striatal medium spiny neuron, annotated with medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
dopamine biosynthetic process GO:0042416 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased dopamine biosynthetic process (GO:0042416). GO:0042416 is a biological process from the Gene Ontology. ↓ DECREASED
striatum UBERON:0002435 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in striatum (UBERON:0002435). UBERON:0002435 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:22166450 SUPPORT Human Clinical
"caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7), the phenotype is usually characterized by levodopa-responsive parkinsonism without atypical features"
Establishes the levodopa-responsive parkinsonian endpoint. The source covers all three recessive genes together and explicitly includes DJ-1 (PARK7).
PMID:29644727 SUPPORT Human Clinical
"an overall clinically typical form of PD with excellent treatment response, dystonia and dyskinesia being relatively common and cognitive decline relatively uncommon"
Systematic-review confirmation of the levodopa-responsive circuit phenotype with common dystonia and dyskinesia. Scope note: the review pools PARK-Parkin, PARK-PINK1 and PARK-DJ1.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for PARK7-Related Early-Onset Parkinson Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Musculoskeletal 1
Rigidity HP:0002063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rigidity (HP:0002063). HP:0002063 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31484320 SUPPORT Other
"PD patients with DJ-1 mutations exhibit an early onset of dyskinesia, rigidity, and tremors"
Names rigidity explicitly among the early features of DJ-1 mutation carriers.
Nervous System 8
Parkinsonism HP:0001300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism (HP:0001300), qualified as course progressive; young adult onset, mean 30.0y. HP:0001300 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: YOUNG ADULT; mean 30.0y
Show evidence (3 references)
PMID:22166450 SUPPORT Human Clinical
"caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7), the phenotype is usually characterized by levodopa-responsive parkinsonism without atypical features"
Directly names DJ-1 (PARK7) as producing levodopa-responsive parkinsonism without atypical features.
PMID:30928208 SUPPORT Human Clinical
"Two brothers of Iranian descent presented at age 29 years with Parkinsonism associated with high-pitched voice and hypomimia."
Case-level confirmation of the parkinsonian presentation and the young-adult onset age in a genetically confirmed PARK7 family.
PMID:29644727 SUPPORT Human Clinical
"early onset (median age at onset of ∼30 years for carriers of at least 2 mutations in any of the 3 genes)"
Quantifies the onset age recorded in the structured `onset` descriptor. Scope note: pooled across the three recessive PD genes, which include DJ1.
Bradykinesia HP:0002067 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bradykinesia (HP:0002067). HP:0002067 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:19694908 SUPPORT Other
"typical parkinsonian features (i.e., resting tremor, akinesia, muscle rigidity, and postural instability)"
Lists akinesia (of which bradykinesia is the partial form) among the typical parkinsonian features of patients carrying mutations in the three recessive PD genes, which include DJ-1. Tagged OTHER because the quoted clause is the authors' summary of the clinical literature, not a result of their mouse experiment.
PMID:29644727 SUPPORT Human Clinical
"an overall clinically typical form of PD"
Bradykinesia is definitional to a "clinically typical form of PD". Marked PARTIAL because the review does not itemise bradykinesia separately and pools the three recessive genes.
Tremor Resting tremor HP:0002322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Resting tremor (HP:0002322). HP:0002322 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31484320 SUPPORT Other
"PD patients with DJ-1 mutations exhibit an early onset of dyskinesia, rigidity, and tremors"
Names tremor among the early features of DJ-1 mutation carriers.
PMID:19694908 SUPPORT Other
"typical parkinsonian features (i.e., resting tremor, akinesia, muscle rigidity, and postural instability)"
Names resting tremor specifically among the typical features of patients with recessive PD gene mutations including DJ-1.
Dystonia HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332). HP:0001332 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29644727 SUPPORT Human Clinical
"dystonia and dyskinesia being relatively common"
Systematic review of >1100 recessive PD patients (Parkin, PINK1, DJ1) reports dystonia as relatively common.
PMID:22956510 SUPPORT Human Clinical
"EOPD mutation carriers were more likely to present with rigidity and dystonia"
Cohort evidence that recessive-gene mutation carriers present with dystonia more often than non-carriers. Marked PARTIAL because only 7 mutation carriers were identified and none carried PARK7 variants.
Levodopa-Induced Dyskinesia HP:0100660 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dyskinesia (HP:0100660). HP:0100660 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29644727 SUPPORT Human Clinical
"dystonia and dyskinesia being relatively common"
Systematic review reports dyskinesia as relatively common in the recessive early-onset forms including PARK-DJ1.
PMID:31484320 SUPPORT Other
"PD patients with DJ-1 mutations exhibit an early onset of dyskinesia"
Specifically attributes early-onset dyskinesia to DJ-1 mutation carriers.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31484320 SUPPORT Other
"followed by later manifestation of psychiatric symptoms, such as psychotic disturbance, anxiety, and cognitive decline"
Names anxiety among the psychiatric non-motor features of DJ-1 mutation carriers.
Psychotic Disturbance Psychosis HP:0000709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31484320 SUPPORT Other
"psychiatric symptoms, such as psychotic disturbance, anxiety, and cognitive decline"
Names psychotic disturbance among the psychiatric features of DJ-1 mutation carriers.
Cognitive Decline Cognitive impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Recorded here as an unresolved tension between a DJ-1-focused review and the pooled MDSGene data; a PARK7-only frequency band was deliberately not assigned.
Show evidence (2 references)
PMID:31484320 SUPPORT Other
"psychiatric symptoms, such as psychotic disturbance, anxiety, and cognitive decline"
Names cognitive decline among the later features of DJ-1 mutation carriers.
PMID:29644727 SUPPORT Human Clinical
"cognitive decline relatively uncommon"
Counterweight evidence: the pooled recessive-PD systematic review found cognitive decline relatively uncommon, tempering the review-level claim above.
Other 3
Levodopa-Responsive Parkinsonism Parkinsonism with favorable response to dopaminergic medication HP:0002548 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism with favorable response to dopaminergic medication (HP:0002548). HP:0002548 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31484320 SUPPORT Other
"generally respond well to L-DOPA treatment"
Review statement on levodopa responsiveness in DJ-1 mutation carriers.
PMID:30928208 SUPPORT Human Clinical
"displayed typical levodopa responsive slowly-progressive Parkinsonism"
Longitudinal (6- and 15-year) confirmation of durable levodopa response in confirmed PARK7 patients.
Hypomimia Hypomimic face HP:0000338 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypomimic face (HP:0000338). HP:0000338 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30928208 SUPPORT Human Clinical
"Parkinsonism associated with high-pitched voice and hypomimia"
Documents hypomimia in genetically confirmed PARK7 patients.
High Non-Motor Symptom Burden FREQUENT
The frequency band is supported by the explicit 57% figure in the quoted sentence, per the frequency-evidence guidelines. No `term:` is bound deliberately: "non-motor symptoms" as an aggregate has no specific HPO class, and the only available ancestor (HP:0000707, Abnormality of the nervous system) is one step from the phenotypic-abnormality root and would convey nothing while polluting HPO-based exports. Prefer no term over a too-general one. The constituent features (anxiety, psychosis, cognitive impairment) are curated individually above with specific terms.
Show evidence (1 reference)
PMID:31484320 SUPPORT Other
"found that DJ-1 mutation carriers exhibit the highest percentage overall (57%) of non-motor symptoms"
Direct quantitative support for the FREQUENT band (57% falls in the HPO 30-79% range) and for the claim that DJ-1 carriers have the highest non-motor burden of the three recessive genotypes.
🧬

Genetic Associations

1
PARK7 (Causative)
Gene: PARK7 hgnc:16369 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PARK7 (hgnc:16369). hgnc:16369 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (5 references)
CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z SUPPORT Other
"PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
ClinGen's Parkinson's Disease Gene Curation Expert Panel classifies the PARK7-Parkinson disease gene-disease relationship as Definitive with autosomal recessive inheritance.
PMID:12446870 SUPPORT Human Clinical
"The DJ-1 gene encodes a ubiquitous, highly conserved protein."
Identifies the gene product and its ubiquitous, highly conserved character, which underpins the multi-system expression of DJ-1.
PMID:22166450 SUPPORT Human Clinical
"Since point mutations and genomic rearrangements can be present, sequencing and exon dosage are both required for accurate mutational screening of these genes."
Supports the diagnostic-testing implication of the mutational spectrum: sequencing alone will miss the large deletions.
+ 2 more references
💊

Medical Actions

3
Levodopa-Carbidopa
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: levodopa CHEBI:15765 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses levodopa, annotated with L-dopa (CHEBI:15765). CHEBI:15765 is a therapeutic agent from Chemical Entities of Biological Interest. carbidopa CHEBI:3395 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses carbidopa (CHEBI:3395). CHEBI:3395 is a therapeutic agent from Chemical Entities of Biological Interest.
Dopamine replacement with levodopa combined with the peripheral decarboxylase inhibitor carbidopa is the mainstay of treatment and works by restoring striatal dopaminergic transmission downstream of the lost nigrostriatal projection. PARK-DJ1 parkinsonism is characteristically and durably levodopa-responsive, documented over follow-up periods of six and fifteen years in a genetically confirmed family. Because onset is early and the disease course long, levodopa-induced dyskinesia is a common management problem in this population and argues for careful dose titration.
Mechanism Target:
MODULATES Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction — Exogenous levodopa is decarboxylated to dopamine in surviving terminals and other striatal cells, restoring dopaminergic tone to the basal ganglia motor circuit. It is purely symptomatic: it does not address the upstream DJ-1 loss, the oxidative stress, or the ongoing nigrostriatal degeneration.
Target Phenotypes: Parkinsonism HP:0001300 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Parkinsonism (HP:0001300). HP:0001300 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:30928208 SUPPORT Human Clinical
"The brothers were followed over a six and fifteen-year period and displayed typical levodopa responsive slowly-progressive Parkinsonism."
Longitudinal human evidence for sustained levodopa responsiveness in genetically confirmed PARK7 disease.
PMID:22166450 SUPPORT Human Clinical
"the phenotype is usually characterized by levodopa-responsive parkinsonism without atypical features"
Establishes levodopa responsiveness as the expected treatment response across the recessive early-onset forms including DJ-1 (PARK7).
Dopamine Agonist Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pramipexole CHEBI:8356 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pramipexole (CHEBI:8356). CHEBI:8356 is a therapeutic agent from Chemical Entities of Biological Interest.
Non-ergot dopamine agonists such as pramipexole act directly on postsynaptic striatal dopamine receptors and are commonly used in early-onset Parkinson disease, often as initial therapy or as a levodopa-sparing adjunct intended to delay motor complications in patients facing decades of treatment. The mechanistic rationale is identical to levodopa's - replacing dopaminergic tone at the striatal node - but without requiring presynaptic conversion.
Mechanism Target:
MODULATES Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction — Direct postsynaptic dopamine receptor agonism restores basal ganglia circuit signalling without depending on residual presynaptic dopamine synthesis capacity.
Show evidence (1 reference)
PMID:22166450 SUPPORT Human Clinical
"the phenotype is usually characterized by levodopa-responsive parkinsonism without atypical features"
Indirect support only: the source establishes that the underlying deficit is a dopaminergic one that responds to dopamine replacement, which is the rationale for dopamine agonists, but it does not evaluate agonists specifically in PARK7 disease. Marked PARTIAL accordingly.
Genetic Counseling
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counselling for an autosomal recessive condition: recurrence risk for siblings of an affected proband is 25%, both parents are obligate carriers, and consanguinity is a common context. Counselling also covers the implications of the small and incompletely characterised PARK7 patient corpus for prognostic advice, and carrier testing for at-risk relatives. The molecular testing strategy that establishes the diagnosis is curated separately under `diagnosis:`.
Show evidence (1 reference)
PMID:30928208 SUPPORT Human Clinical
"Bi-allelic mutations in PARK7 are a rare cause of autosomal recessive early onset Parkinson's disease (EO-PD). To date, 30 individuals harbouring 20 unique causative variants have been described."
Establishes the biallelic (autosomal recessive) transmission that determines the 25% sibling recurrence risk counselled here, and the small size of the reported corpus that limits prognostic counselling.
🔬

Diagnosis

3
Molecular Genetic Testing (Sequencing plus Exon Dosage)
Establishing a PARK7 diagnosis requires demonstrating biallelic pathogenic variants, and requires BOTH sequencing and exon-dosage (copy-number) analysis: the mutational spectrum includes large genomic rearrangements - the founding Dutch family carried a 14,082 bp deletion - that sequencing alone will miss, so a sequencing-only panel can return a false negative or report an apparently heterozygous carrier when the second allele is a deletion.
Show evidence (1 reference)
PMID:22166450 SUPPORT Human Clinical
"Since point mutations and genomic rearrangements can be present, sequencing and exon dosage are both required for accurate mutational screening of these genes."
Directly specifies the two-pronged molecular testing strategy needed to make the diagnosis. Scope note: the source covers all three recessive genes (PARK2/PRKN, PINK1, PARK7) together.
Clinical Selection of Patients for Recessive-Gene Testing
Because PARK7 explains well under 1% of early-onset Parkinson disease, the clinical features that raise the pretest probability of a recessive monogenic cause matter more than for commoner genes: age at onset under 40, an affected first-degree relative or sibling, and above all parental consanguinity, which raises the mutation yield to 50%. Mutation carriers are also more likely to present with rigidity and dystonia.
Show evidence (1 reference)
PMID:22956510 SUPPORT Human Clinical
"Mutations were more common in patients with age at onset (AAO) < 40 (9.5%), an affected first-degree relative (6.9%), an affected sibling (28.6%), or parental consanguinity (50%)."
Quantifies the clinical features that should raise the pretest probability of a recessive monogenic cause and prompt testing. Scope note: the cohort covers PARK2/PRKN, PINK1, PARK7 and LRRK2 together.
Documentation of Levodopa Responsiveness
A sustained, unambiguous response to levodopa is a practical diagnostic discriminator that separates PARK-DJ1 from the atypical parkinsonian syndromes in the differential of a young patient with parkinsonism, and has been documented over six- and fifteen-year follow-up in a genetically confirmed PARK7 family.
Dopamine-transporter imaging (DaT SPECT) is the standard workup step that would confirm the presynaptic nigrostriatal deficit this entry's `Nigrostriatal Dopaminergic Neurodegeneration` node infers, but no PARK7-specific imaging series with a quotable result was found; it is deliberately not asserted here and is instead listed as a proposed experiment under the human/model-mismatch discussion.
Show evidence (2 references)
PMID:30928208 SUPPORT Human Clinical
"The brothers were followed over a six and fifteen-year period and displayed typical levodopa responsive slowly-progressive Parkinsonism."
Longitudinal documentation of the levodopa response that supports the clinical diagnosis in genetically confirmed PARK7 disease.
PMID:22166450 SUPPORT Human Clinical
"the phenotype is usually characterized by levodopa-responsive parkinsonism without atypical features"
Establishes absence of atypical features plus levodopa responsiveness as the expected diagnostic picture across the recessive early-onset forms including DJ-1 (PARK7).
📊

Prevalence

1
Worldwide
Point Prevalence Ultra Rare
No population prevalence estimate for PARK7-related early-onset Parkinson disease exists. The qualitative ULTRA_RARE band is assigned from the size of the reported patient corpus - 30 individuals with 20 unique causative variants described worldwide as of 2019 - rather than from a measured rate. No numeric rate_per_100000 is asserted, deliberately: converting a case count into a population rate would be fabrication. The gene-level share of early-onset Parkinson disease cases is curated as structured `case_fractions` on the PARK7 `genetic` record instead, which is the appropriate slot for a genetic-spectrum denominator. For the two-step rarity: early-onset Parkinson disease itself accounts for approximately 3.6% of all Parkinson disease (PMID:22956510, "Approximately 3.6% of patients with Parkinson's disease develop symptoms before age 45"), and PARK7 explains only ~0.4% of that early-onset group. That 3.6% figure is a proportion of PD cases describing the PARENT population, not an occurrence measure for this disease, so it is recorded here as a note rather than as a second Prevalence record.
Show evidence (1 reference)
PMID:30928208 SUPPORT Human Clinical
"Bi-allelic mutations in PARK7 are a rare cause of autosomal recessive early onset Parkinson's disease (EO-PD). To date, 30 individuals harbouring 20 unique causative variants have been described."
Establishes rarity and gives the reported-case count that grounds the ULTRA_RARE qualitative band.
{ }

Source YAML

click to show 
name: PARK7-Related Early-Onset Parkinson Disease
creation_date: "2026-07-31T00:00:00Z"
description: >-
  PARK7-related early-onset Parkinson disease (PARK-DJ1, autosomal recessive
  early-onset Parkinson disease 7) is a rare monogenic parkinsonism caused by
  biallelic loss-of-function variants in PARK7, which encodes DJ-1. DJ-1 is a
  small, ubiquitously expressed, homodimeric protein whose conserved cysteine
  at position 106 (Cys106) is progressively oxidized (Cys-SOH to Cys-SO2H to
  Cys-SO3H), making it a redox sensor and cytoprotective effector: oxidized
  DJ-1 relocalizes to the outer mitochondrial membrane, stabilizes the
  antioxidant master regulator NRF2 by preventing KEAP1-mediated
  ubiquitination, and acts as a redox-dependent molecular chaperone that
  inhibits alpha-synuclein aggregation. DJ-1 also carries a
  glutathione-independent catalytic activity toward the reactive dicarbonyl
  methylglyoxal, though whether this constitutes a glyoxalase (free
  methylglyoxal to lactate) or a protein deglycase (repair of glycated
  residues) activity remains an active and unresolved controversy. Biallelic
  loss of DJ-1 removes this multi-pronged cytoprotective buffer, leaving
  substantia nigra pars compacta dopaminergic neurons - already burdened by
  high bioenergetic demand and dopamine-derived oxidant load - vulnerable to
  oxidative and dicarbonyl stress and mitochondrial dysfunction. The result is
  nigrostriatal dopaminergic degeneration, striatal dopamine deficiency, and
  levodopa-responsive parkinsonism with onset typically in the third decade,
  often accompanied by dystonia, early dyskinesia, and a high burden of
  psychiatric and cognitive non-motor features. PARK7 is the rarest of the
  three classic autosomal recessive early-onset Parkinson disease genes,
  accounting for roughly 0.4% of early-onset cases in a systematic review.
category: Mendelian
parents:
- Neurodegenerative Disease
- Movement Disorder
- Autosomal Recessive Early-Onset Parkinsonism
disease_term:
  preferred_term: autosomal recessive early-onset Parkinson disease 7
  term:
    id: MONDO:0011658
    label: autosomal recessive early-onset Parkinson disease 7
synonyms:
- PARK7
- PARK-DJ1
- PARK7 Parkinson disease
- DJ-1-related early-onset Parkinson disease
- Parkinson disease caused by mutation in PARK7
- autosomal recessive early-onset Parkinson disease type 7
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
notes: >-
  Lump-vs-split rationale. This entry is deliberately kept SEPARATE from the
  existing `Parkinson's Disease` entry (MONDO:0005180), which curates the
  common, largely sporadic, late-onset alpha-synucleinopathy at the broad
  MONDO level and lists PARK7 only as one genetic axis among SNCA, LRRK2,
  PRKN, PINK1, VPS35 and GBA1. The two entries are complementary rather than
  duplicative: (1) MONDO models PARK-DJ1 as a distinct entity
  (MONDO:0011658, a child of MONDO:0017279 young-onset Parkinson disease)
  defined by its causal gene; (2) the primary lesion here is a defined
  molecular loss of function in a redox-sensing cytoprotective protein, not
  the multifactorial exposome-plus-polygenic-risk architecture of common PD;
  (3) the phenotype differs in onset age (median ~30 years), inheritance
  (autosomal recessive rather than sporadic/dominant), and non-motor burden;
  and (4) the alpha-synuclein/Lewy-body arm that defines common PD is
  essentially unverified in PARK-DJ1 - only a single DJ-1 mutation brain
  (L172Q) has ever been examined neuropathologically. This entry therefore
  curates the DJ-1 biochemistry and its causal chain in depth and conforms to
  the shared `parkinsonism_dopaminergic_degeneration` module for the
  nigrostriatal-to-parkinsonism final common pathway, rather than restating
  the synucleinopathy content of the `Parkinson's Disease` entry.

  NEC preflight (the PARK numbered series is a high named-entity-confusion
  risk class): MONDO:0011658 was verified with OAK to carry
  `relationship: RO:0004003 HGNC:16369 ! PARK7`, `xref: OMIM:606324`, and the
  synonyms "PARK7 Parkinson disease" / "PARK7". All curated evidence was
  screened to be about PARK7/DJ-1 and not the locus-adjacent PARK2/PRKN or
  PARK6/PINK1 entities; where a source covers all three recessive genes
  (PMID:22166450, PMID:22956510, PMID:29644727, PMID:19694908) that
  multi-gene scope is stated explicitly in the evidence `explanation`.

  Sourcing provenance (recorded decisions, not omissions). (a) NO
  deep-research artifact was generated for this entry: it was curated
  directly from primary literature located by targeted PubMed
  title/keyword search, with every PMID fetched via `just fetch-reference`
  and every snippet verified against the cached abstract. This was
  deliberate given the high named-entity-confusion risk of the PARK
  numbered series - DR tools resolving "PARK7" or "early-onset
  parkinsonism" are exactly the failure mode #3889 describes, and several
  PMIDs recalled from memory during curation turned out on verification to
  point at unrelated papers and were discarded and re-resolved by title
  search. (b) The GeneReviews chapter PMID:20301402 (Monogenic Parkinson
  Disease Overview) is tagged in `references:` but deliberately cited by no
  evidence item: there is no PARK7-specific GeneReviews chapter, and the
  cached abstract for the monogenic overview is a bare statement of the
  chapter's purpose with no quotable Clinical Characteristics, Diagnosis,
  Management or Genetic Counseling content. Quoting a purpose statement
  would add noise rather than evidence, so it is retained as a tagged
  baseline reference only.

references:
- reference: PMID:20301402
  title: Monogenic Parkinson Disease Overview
  tags:
  - GeneReviews
- reference: PMID:31484320
  title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives"
- reference: PMID:29644727
  title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review"

mechanistic_hypotheses:
- hypothesis_group_id: dj1_oxidative_stress_cytoprotection_model
  hypothesis_label: Canonical DJ-1 Redox-Sensor and Cytoprotection Model
  status: CANONICAL
  description: >-
    The widely accepted model: DJ-1 is an oxidative-stress sensor whose
    conserved Cys106 is oxidized to cysteine-sulfinic acid under oxidant
    stress, which signals mitochondrial relocalization and cytoprotection;
    DJ-1 additionally stabilizes NRF2 (blocking KEAP1-mediated
    ubiquitination) to sustain antioxidant transcription, and acts as a
    redox-dependent chaperone limiting alpha-synuclein aggregation. Biallelic
    loss of DJ-1 removes this buffer, producing oxidative stress and
    mitochondrial dysfunction in nigral dopaminergic neurons. This model is
    the basis for the trigger-to-effector chain curated in this entry and is
    not seriously disputed at the level of "DJ-1 is cytoprotective under
    oxidative stress" - the disputes concern the biochemical mechanism (see
    the two dicarbonyl hypotheses below).
  evidence:
  - reference: PMID:15181200
    reference_title: "The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We suggest that DJ-1 protects against neuronal death, and that this is
      signaled by acidification of the key cysteine residue, C106.
    explanation: >-
      Establishes the Cys106-oxidation-signalled cytoprotection that anchors
      the canonical model.
- hypothesis_group_id: dj1_glyoxalase_dicarbonyl_detoxification
  hypothesis_label: DJ-1 as a Glutathione-Independent Glyoxalase (Dicarbonyl Detoxification)
  status: ALTERNATIVE
  description: >-
    A competing biochemical account of DJ-1's catalytic activity: DJ-1 and
    its orthologs act as glutathione-independent glyoxalases that convert
    free glyoxal and methylglyoxal directly to glycolate and lactate, so that
    DJ-1 loss causes accumulation of reactive dicarbonyls and downstream
    glycation damage in dopaminergic neurons. This is supported by
    Michaelis-Menten kinetics on purified DJ-1, by protection of SH-SY5Y
    cells and C. elegans from glyoxal challenge, and by the observation that
    dopaminergic neurons degenerate in DJ-1-homolog-null worms exposed to
    sublethal glyoxal. Kinetic work reconciling the two dicarbonyl accounts
    (PMID:31653696) favours THIS activity as the real one and attributes the
    apparent deglycase activity to a rapid equilibrium artifact - but even
    that study found that DJ-1 loss did not protect human cells from acute
    methylglyoxal toxicity, and a Drosophila in vivo study found no
    contribution of DJ-1 to methylglyoxal detoxification at all. The relative
    contribution of dicarbonyl stress to human PARK-DJ1 neurodegeneration is
    therefore NOT settled.
  evidence:
  - reference: PMID:22523093
    reference_title: Human DJ-1 and its homologs are novel glyoxalases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      human DJ-1 and its homologs of the mouse and Caenorhabditis elegans are
      novel types of glyoxalase, converting glyoxal or methylglyoxal to
      glycolic or lactic acid, respectively, in the absence of glutathione
    explanation: >-
      The originating biochemical claim for the glutathione-independent
      glyoxalase hypothesis.
  - reference: PMID:31653696
    reference_title: The apparent deglycase activity of DJ-1 results from the conversion of free methylglyoxal present in fast equilibrium with hemithioacetals and hemiaminals.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We found that removal of free MGO by DJ-1's glyoxalase activity forces
      immediate spontaneous decomposition of hemithioacetals due to the shift
      in equilibrium position.
    explanation: >-
      Kinetic analysis that adjudicates between the two dicarbonyl hypotheses
      in favour of glyoxalase activity, while explaining the deglycase
      observations as an equilibrium artifact. Marked PARTIAL because the
      same paper reports that DJ-1 knockout did not protect human cells from
      acute methylglyoxal toxicity, so it supports the enzymology without
      supporting a cellular protective role.
- hypothesis_group_id: dj1_protein_deglycase_repair
  hypothesis_label: DJ-1 as a Protein Deglycase Repairing Glycated Residues (Contested)
  status: ALTERNATIVE
  description: >-
    The rival biochemical account: rather than scavenging free dicarbonyls,
    DJ-1 acts on early glycation intermediates already formed on proteins,
    deglycating cysteine, arginine and lysine residues and thereby
    reactivating damaged proteins, so that PARK-DJ1 parkinsonism would result
    from excessive protein glycation. This hypothesis has been directly and
    repeatedly challenged: a Drosophila in vivo study detected no
    contribution of DJ-1 to methylglyoxal-adduct accumulation or survival and
    attributed the reported deglycation activity to a TRIS buffer artifact,
    and an independent kinetic study concluded that DJ-1 does not possess
    protein deglycase activity, with the apparent activity arising from the
    fast equilibrium between free methylglyoxal and hemithioacetals. It is
    retained here as an explicitly contested ALTERNATIVE rather than removed,
    because it remains a live disagreement in the literature and because the
    deglycase framing continues to be cited in reviews.
  evidence:
  - reference: PMID:25416785
    reference_title: "Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we show that human DJ-1 is a protein deglycase that repairs
      methylglyoxal- and glyoxal-glycated amino acids and proteins by acting
      on early glycation intermediates
    explanation: The originating claim for the protein-deglycase hypothesis.
  - reference: PMID:27903648
    reference_title: Evidence Against a Role for the Parkinsonism-associated Protein DJ-1 in Methylglyoxal Detoxification.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using both DJ-1 knockdown in Drosophila cells in culture, and DJ-1β
      knock-out flies, we could detect no contribution of DJ-1 to survival to
      MG challenge or to accumulation of MG protein adducts.
    explanation: >-
      In vivo Drosophila refutation of the deglycase/detoxification role,
      including attribution of the reported activity to a buffer artifact.
  - reference: PMID:31653696
    reference_title: The apparent deglycase activity of DJ-1 results from the conversion of free methylglyoxal present in fast equilibrium with hemithioacetals and hemiaminals.
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: >-
      Combined, our results suggest that DJ-1 does not possess protein
      deglycase activity.
    explanation: Independent kinetic refutation of the deglycase hypothesis.

pathophysiology:
- name: Biallelic PARK7 Loss of Function
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    The initiating lesion is complete or near-complete loss of functional
    DJ-1 protein from biallelic PARK7 variants. Two mechanistic classes were
    identified in the founding families and remain representative: large
    genomic deletions removing the 5' portion of the gene (a 14,082 bp
    deletion segregating in a Dutch kindred), which abolish transcript
    production outright; and destabilising missense substitutions, prototyped
    by the homozygous L166P change in an Italian family. L166P sits in a
    C-terminal helix-kink-helix motif; helix-breaking substitutions there
    dramatically lower steady-state DJ-1 levels through accelerated
    degradation involving in part the proteasome, and abolish DJ-1
    homodimerisation. Because DJ-1 is obligately dimeric for function, both
    classes converge on functional nullity.
  gene:
    preferred_term: PARK7
    term:
      id: hgnc:16369
      label: PARK7
  molecular_functions:
  - preferred_term: DJ-1 protein homodimerization
    term:
      id: GO:0042803
      label: protein homodimerization activity
    modifier: DECREASED
  evidence:
  - reference: PMID:12446870
    reference_title: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we show that DJ-1 mutations are associated with PARK7, a monogenic form
      of human parkinsonism.
    explanation: >-
      The founding human genetic evidence establishing PARK7/DJ-1 as the
      causal gene of this entity.
  - reference: PMID:12446870
    reference_title: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings indicate that loss of DJ-1 function leads to
      neurodegeneration.
    explanation: >-
      States the loss-of-function direction of effect that makes this a
      trigger node rather than a gain-of-function lesion.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      due to a deletion of 14,082 bp in a Dutch family or a homozygous point
      mutation (L166P) in an Italian family
    explanation: >-
      Documents the two representative variant classes (large deletion and
      destabilising missense) in the founding families.
  - reference: PMID:17331951
    reference_title: Structural determinants of the C-terminal helix-kink-helix motif essential for protein stability and survival promoting activity of DJ-1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The decreased steady-state levels were due to accelerated protein
      degradation involving in part the proteasome. G-helix breaking DJ-1
      mutations abolished dimer formation.
    explanation: >-
      Mechanistic account of how destabilising C-terminal missense variants
      such as L166P produce functional nullity through degradation and loss
      of dimerisation.
  downstream:
  - target: Loss of DJ-1 Cys106 Redox Sensing and Cytoprotection
    causal_link_type: DIRECT
    description: >-
      Absence of functional DJ-1 protein directly removes the Cys106
      redox-sensing, mitochondrial-relocalisation, and chaperone functions.
  - target: Loss of DJ-1 Dicarbonyl Detoxification Capacity
    causal_link_type: DIRECT
    hypothesis_groups:
    - dj1_glyoxalase_dicarbonyl_detoxification
    - dj1_protein_deglycase_repair
    description: >-
      Under either dicarbonyl hypothesis, absence of DJ-1 removes its
      catalytic activity toward methylglyoxal and glyoxal. This edge is
      deliberately assigned to BOTH contested dicarbonyl hypothesis groups
      rather than asserted as an established part of the canonical chain.

- name: Loss of DJ-1 Cys106 Redox Sensing and Cytoprotection
  biological_scale: MOLECULAR
  role: amplifier
  conforms_to: "parkinsonism_dopaminergic_degeneration#Dopaminergic Neuronal Vulnerability and Toxic Insult"
  description: >-
    In wild-type cells the conserved Cys106 of DJ-1 is the preferential
    target of oxidative modification, stepping through sulfenic (Cys-SOH),
    sulfinic (Cys-SO2H) and sulfonic (Cys-SO3H) states. Formation of
    cysteine-sulfinic acid at Cys106 is the switch that drives DJ-1 to the
    outer mitochondrial membrane and confers protection against the complex I
    inhibitor MPP+; an artificial C106A substitution abolishes both the pI
    shift and the protection, and behaves as a partial dominant negative.
    DJ-1 also functions as a redox-sensitive molecular chaperone activated in
    an oxidising cytoplasmic environment, with chaperone activity extending to
    alpha-synuclein. Loss of DJ-1 therefore removes an oxidant-triggered,
    self-amplifying cytoprotective response precisely when the cell most
    needs it. This node substitutes the module's generic toxic insult with a
    cell-intrinsic genetic one: the same dopaminergic vulnerability is
    reached by removing endogenous defence rather than by adding a poison.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
    modifier: DECREASED
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:15181200
    reference_title: "The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      oxidation-induced mitochondrial relocalization of DJ-1 and protection
      against cell death were abrogated in C106A but not C53A or C46A.
    explanation: >-
      Demonstrates that Cys106 specifically is required for the
      oxidation-triggered mitochondrial relocalisation and cytoprotection
      lost in DJ-1 deficiency.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cys106 is the preferential target for oxidative protein modification
      and is required for DJ-1 mediated protection from oxidative stress
    explanation: >-
      Review-level confirmation that Cys106 is the redox-sensing residue
      required for DJ-1's protective function.
  - reference: PMID:15502874
    reference_title: DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Here we show that DJ-1 functions as a redox-sensitive molecular
      chaperone that is activated in an oxidative cytoplasmic environment.
    explanation: >-
      Establishes the redox-dependent chaperone arm of DJ-1 function, whose
      loss is part of this node.
  - reference: PMID:40159591
    reference_title: Redox modulatory role of DJ-1 in Parkinson's disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      mutations like L166P cause loss of antioxidant activity and increased
      Reactive Oxygen Species (ROS) accumulation with subsequent
      mitochondrial dysfunction in dopaminergic neurons
    explanation: >-
      Directly links the prototypical destabilising PARK7 variant to loss of
      antioxidant capacity, ROS accumulation and mitochondrial dysfunction in
      dopaminergic neurons.
  downstream:
  - target: Impaired NRF2 Antioxidant Transcriptional Response
    causal_link_type: DIRECT
    description: >-
      Without DJ-1, NRF2 is not shielded from KEAP1 and the antioxidant
      transcriptional programme it drives collapses.
  - target: Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
    causal_link_type: DIRECT
    description: >-
      Loss of the Cys106-triggered mitochondrial cytoprotective response
      leaves dopaminergic neurons exposed to oxidant and bioenergetic injury.

- name: Loss of DJ-1 Dicarbonyl Detoxification Capacity
  biological_scale: MOLECULAR
  role: amplifier
  description: >-
    DJ-1 carries a glutathione-independent catalytic activity toward the
    reactive dicarbonyls methylglyoxal and glyoxal, byproducts of glycolysis
    that non-enzymatically glycate cysteine, arginine and lysine residues.
    The nature of that activity is genuinely disputed: one account has DJ-1
    scavenging free dicarbonyl (glyoxalase III activity, converting
    methylglyoxal to lactate), while the other has it repairing already-formed
    glycation adducts on proteins (protein deglycase activity). Kinetic work
    favours the glyoxalase account and explains the deglycase observations as
    an artifact of the fast equilibrium between free methylglyoxal and
    hemithioacetals; in vivo Drosophila data question whether either activity
    matters for dicarbonyl handling at all. This node is therefore modelled
    as a hypothesis-scoped amplifier rather than an established step: it is
    included because the biochemistry is real and disease-relevant, and it is
    tagged to its competing hypothesis groups so downstream tooling does not
    read it as settled.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  molecular_functions:
  - preferred_term: glyoxalase III activity (glutathione-independent)
    term:
      id: GO:0019172
      label: glyoxalase III activity
    modifier: DECREASED
  - preferred_term: protein deglycase activity (contested)
    term:
      id: GO:0036524
      label: protein deglycase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: methylglyoxal catabolic process
    term:
      id: GO:0051596
      label: methylglyoxal catabolic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: methylglyoxal
    term:
      id: CHEBI:17158
      label: methylglyoxal
    modifier: INCREASED
  evidence:
  - reference: PMID:22523093
    reference_title: Human DJ-1 and its homologs are novel glyoxalases.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Sub-lethal doses of glyoxals caused significant degeneration of the
      dopaminergic neurons in C. elegans lacking cDJR-1.2, another DJ-1
      homolog expressed primarily in the head region, including neurons.
    explanation: >-
      Model-organism evidence tying loss of a DJ-1 homolog plus dicarbonyl
      exposure specifically to dopaminergic neuron degeneration. Kept as
      supporting evidence for the hypothesis-scoped node, not for the
      canonical human chain.
  - reference: PMID:27903648
    reference_title: Evidence Against a Role for the Parkinsonism-associated Protein DJ-1 in Methylglyoxal Detoxification.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Furthermore, we provide data suggesting that the previously reported
      deglycation activity of DJ-1 can be ascribed to a TRIS buffer artifact.
    explanation: >-
      Explicit refutation retained on the node so the controversy is visible
      in the pathograph rather than buried in prose.
  downstream:
  - target: Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - dj1_glyoxalase_dicarbonyl_detoxification
    - dj1_protein_deglycase_repair
    description: >-
      Under either dicarbonyl hypothesis, accumulating methylglyoxal and
      protein glycation would add to the carbonyl and oxidant burden on
      nigral dopaminergic neurons. Modelled as indirect and hypothesis-scoped
      because the in vivo contribution in human PARK-DJ1 is unestablished.

- name: Impaired NRF2 Antioxidant Transcriptional Response
  biological_scale: MOLECULAR
  role: amplifier
  description: >-
    DJ-1 stabilises NFE2L2 (NRF2), the master transcriptional regulator of
    the cellular antioxidant response, by preventing its association with the
    inhibitor KEAP1 and its subsequent ubiquitination. In the absence of
    intact DJ-1, NRF2 protein is unstable and antioxidant transcriptional
    responses fall both basally and after induction, with measurable deficits
    in the detoxification enzyme NQO1 and, in the wider DJ-1/NRF2 literature,
    in glutathione peroxidase, superoxide dismutase and heme oxygenase-1.
    This converts an acute, recoverable oxidant insult into a chronic
    inability to mount an antioxidant defence.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: NRF2 protein stabilization by DJ-1
    term:
      id: GO:0050821
      label: protein stabilization
    modifier: DECREASED
  - preferred_term: reactive oxygen species metabolic process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:17015834
    reference_title: "DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      DJ-1 stabilizes Nrf2 by preventing association with its inhibitor
      protein, Keap1, and Nrf2's subsequent ubiquitination.
    explanation: >-
      Defines the molecular mechanism of the DJ-1/NRF2 axis lost in DJ-1
      deficiency.
  - reference: PMID:17015834
    reference_title: "DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Without intact DJ-1, Nrf2 protein is unstable, and transcriptional
      responses are thereby decreased both basally and after induction.
    explanation: States the loss-of-function consequence that this node models.
  - reference: PMID:40159591
    reference_title: Redox modulatory role of DJ-1 in Parkinson's disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the DJ-1 or Nrf2 axis, expression of key antioxidant enzymes
      (glutathione peroxidase (GPx), superoxide dismutase (SOD), and heme
      oxygenase-1 (HO-1) in response to oxidative stress is increased, and
      decreased neuronal damage resulting from oxidative stress is achieved.
    explanation: >-
      Identifies the downstream antioxidant enzymes whose induction depends
      on an intact DJ-1/NRF2 axis.
  downstream:
  - target: Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
    causal_link_type: DIRECT
    description: >-
      Failure of NRF2-driven antioxidant transcription leaves reactive oxygen
      species unbuffered in dopaminergic neurons.

- name: Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
  biological_scale: CELLULAR
  role: central_effector
  conforms_to: "parkinsonism_dopaminergic_degeneration#Mitochondrial Complex I Inhibition and Oxidative Stress"
  description: >-
    The convergent cellular lesion is unbuffered oxidative stress with
    mitochondrial dysfunction in substantia nigra pars compacta dopaminergic
    neurons. This is the same convergence node the shared
    parkinsonism_dopaminergic_degeneration module places downstream of
    environmental complex I toxins (MPTP, rotenone, paraquat) - PARK7 loss
    reaches it from the opposite direction, by removing endogenous
    antioxidant defence rather than by adding an exogenous poison. Substantia
    nigra dopaminergic neurons are selectively vulnerable because of their
    high bioenergetic demand and high basal reactive oxygen species load;
    DJ-1 is normally most highly expressed exactly in such
    high-energy-demand, high-ROS cells. Consistent with the human relevance
    of this node, oxidised DJ-1 accumulates in the substantia nigra of ageing
    and idiopathic Parkinson disease brains.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: substantia nigra pars compacta
    term:
      id: UBERON:0002038
      label: substantia nigra
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:40159591
    reference_title: Redox modulatory role of DJ-1 in Parkinson's disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Oxidized DJ-1 (OxiDJ-1) is generated in aging brains, particularly in
      the substantia nigra (SN), and is correlated with PD progression
    explanation: >-
      Anchors the oxidative-stress node to the human substantia nigra rather
      than to cell culture alone.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      DJ-1 is highly expressed in cells with high energy demands, hence cells
      with higher levels of reactive oxygen species.
    explanation: >-
      Explains why loss of DJ-1 preferentially unmasks injury in
      high-bioenergetic-demand, high-ROS cells such as nigral dopaminergic
      neurons.
  - reference: PMID:12446870
    reference_title: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The function of the DJ-1 protein remains unknown, but evidence suggests
      its involvement in the oxidative stress response.
    explanation: >-
      The founding report already placed DJ-1 in the oxidative stress
      response. Marked PARTIAL because it flags the function as then-unknown
      and does not itself demonstrate nigral oxidative injury.
  downstream:
  - target: Nigrostriatal Dopaminergic Neurodegeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Chronic oxidative and bioenergetic stress in a selectively vulnerable
      neuronal population drives its progressive degeneration. Marked
      indirect because the proximate death mechanism in human PARK-DJ1 nigral
      neurons has not been established (see the human/model mismatch
      discussion).

- name: Nigrostriatal Dopaminergic Neurodegeneration
  biological_scale: TISSUE
  role: effector
  conforms_to: "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration"
  description: >-
    Progressive loss of substantia nigra pars compacta dopaminergic neurons
    and their nigrostriatal projection - the shared effector lesion of all
    dopaminergic parkinsonisms. In PARK-DJ1 this is inferred clinically and
    from dopaminergic imaging rather than from neuropathology: only a single
    brain from a patient with a DJ-1 mutation (L172Q) has ever been analysed,
    and it showed Lewy body pathology, so whether PARK-DJ1 is routinely a
    synucleinopathy is unknown. Rodent models are explicitly discordant here:
    DJ-1 knockout mice, and even parkin/DJ-1/PINK1 triple knockout mice up to
    24 months, retain normal numbers of nigral dopaminergic neurons while
    showing dopaminergic functional deficits - a human/model mismatch curated
    as a discussion below.
  cell_types:
  - preferred_term: Dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: substantia nigra pars compacta
    term:
      id: UBERON:0002038
      label: substantia nigra
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      each of which was required for nigral neuron survival in the aging
      human brain
    explanation: >-
      States the premise underlying this node: DJ-1 (alongside parkin and
      PINK1) is required for nigral neuron survival in the ageing human
      brain. Tagged OTHER because the quoted clause is the authors' framing
      of the human genetics, not a result of their mouse experiment.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      has been analyzed thus far, which notably exhibited Lewy body (LB)
      pathology
    explanation: >-
      The only direct human neuropathological observation in PARK-DJ1 (the
      quoted clause refers to the single analysed DJ-1 L172Q brain). Marked
      PARTIAL because a single autopsy cannot establish the general
      neuropathology of the entity.
  downstream:
  - target: Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
    causal_link_type: DIRECT
    description: >-
      Loss of the nigrostriatal projection depletes striatal dopamine.

- name: Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
  biological_scale: TISSUE
  role: effector
  conforms_to: "parkinsonism_dopaminergic_degeneration#Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction"
  description: >-
    Depletion of striatal dopamine unbalances the basal ganglia
    thalamocortical motor circuit and produces the cardinal parkinsonian
    signs - bradykinesia, rigidity, and tremor - with prominent dystonia in
    this early-onset recessive form. Because the deficit is a dopamine
    deficiency in an otherwise responsive circuit, PARK-DJ1 parkinsonism is
    characteristically and durably levodopa-responsive, which is also the
    mechanistic rationale for dopamine replacement therapy. The same circuit
    deficit, chronically over-stimulated by pulsatile levodopa, underlies the
    relatively early motor complications (dyskinesia) reported in this and
    the other recessive early-onset forms. Scale note: tagged TISSUE because
    the node's substrate is the striatum and the basal ganglia
    thalamocortical circuit; the organism-level motor syndrome it produces
    is captured in `phenotypes` rather than bundled into this node.
  cell_types:
  - preferred_term: Striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7),
      the phenotype is usually characterized by levodopa-responsive
      parkinsonism without atypical features
    explanation: >-
      Establishes the levodopa-responsive parkinsonian endpoint. The source
      covers all three recessive genes together and explicitly includes DJ-1
      (PARK7).
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an overall clinically typical form of PD with excellent treatment
      response, dystonia and dyskinesia being relatively common and cognitive
      decline relatively uncommon
    explanation: >-
      Systematic-review confirmation of the levodopa-responsive circuit
      phenotype with common dystonia and dyskinesia. Scope note: the review
      pools PARK-Parkin, PARK-PINK1 and PARK-DJ1.

phenotypes:
- category: Neurologic
  name: Parkinsonism
  description: >-
    The defining clinical syndrome: bradykinesia with rigidity and/or tremor
    arising from nigrostriatal dopamine deficiency. In PARK-DJ1 the syndrome
    is described as clinically typical parkinsonism without atypical
    features, with onset characteristically in the third decade (median age
    at onset around 30 years across the recessive early-onset genes; the
    best-characterised PARK7 family presented at 29).
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
    clinical_course: PROGRESSIVE
    onset:
      onset_category: YOUNG_ADULT
      mean_age_years: 30.0
      notes: >-
        Median age at onset ~30 years reported by the MDSGene systematic
        review for carriers of at least two mutations in Parkin, PINK1 or
        DJ1; the genetically confirmed PARK7 sibling pair presented at 29.
  evidence:
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7),
      the phenotype is usually characterized by levodopa-responsive
      parkinsonism without atypical features
    explanation: >-
      Directly names DJ-1 (PARK7) as producing levodopa-responsive
      parkinsonism without atypical features.
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two brothers of Iranian descent presented at age 29 years with
      Parkinsonism associated with high-pitched voice and hypomimia.
    explanation: >-
      Case-level confirmation of the parkinsonian presentation and the
      young-adult onset age in a genetically confirmed PARK7 family.
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      early onset (median age at onset of ∼30 years for carriers of at least
      2 mutations in any of the 3 genes)
    explanation: >-
      Quantifies the onset age recorded in the structured `onset` descriptor.
      Scope note: pooled across the three recessive PD genes, which include
      DJ1.

- category: Neurologic
  name: Levodopa-Responsive Parkinsonism
  description: >-
    PARK-DJ1 parkinsonism responds well and durably to levodopa, a
    discriminating clinical feature relative to atypical parkinsonian
    syndromes and a direct consequence of the deficit being presynaptic
    dopamine loss in an intact postsynaptic circuit.
  diagnostic: true
  phenotype_term:
    preferred_term: Parkinsonism with favorable response to dopaminergic medication
    term:
      id: HP:0002548
      label: Parkinsonism with favorable response to dopaminergic medication
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: generally respond well to L-DOPA treatment
    explanation: >-
      Review statement on levodopa responsiveness in DJ-1 mutation carriers.
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      displayed typical levodopa responsive slowly-progressive Parkinsonism
    explanation: >-
      Longitudinal (6- and 15-year) confirmation of durable levodopa response
      in confirmed PARK7 patients.

- category: Neurologic
  name: Bradykinesia
  description: >-
    Slowness of voluntary movement, the cardinal parkinsonian sign and part
    of the typical parkinsonian feature set described across the autosomal
    recessive early-onset Parkinson disease genes including DJ-1.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      typical parkinsonian features (i.e., resting tremor, akinesia, muscle
      rigidity, and postural instability)
    explanation: >-
      Lists akinesia (of which bradykinesia is the partial form) among the
      typical parkinsonian features of patients carrying mutations in the
      three recessive PD genes, which include DJ-1. Tagged OTHER because the
      quoted clause is the authors' summary of the clinical literature, not a
      result of their mouse experiment.
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an overall clinically typical form of PD
    explanation: >-
      Bradykinesia is definitional to a "clinically typical form of PD".
      Marked PARTIAL because the review does not itemise bradykinesia
      separately and pools the three recessive genes.

- category: Neurologic
  name: Rigidity
  description: Increased resistance to passive movement, present from early in the course.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      PD patients with DJ-1 mutations exhibit an early onset of dyskinesia,
      rigidity, and tremors
    explanation: >-
      Names rigidity explicitly among the early features of DJ-1 mutation
      carriers.

- category: Neurologic
  name: Tremor
  description: >-
    Tremor is part of the cardinal triad in DJ-1 mutation carriers; rest
    tremor is the classic parkinsonian form.
  phenotype_term:
    preferred_term: Resting tremor
    term:
      id: HP:0002322
      label: Resting tremor
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      PD patients with DJ-1 mutations exhibit an early onset of dyskinesia,
      rigidity, and tremors
    explanation: >-
      Names tremor among the early features of DJ-1 mutation carriers.
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      typical parkinsonian features (i.e., resting tremor, akinesia, muscle
      rigidity, and postural instability)
    explanation: >-
      Names resting tremor specifically among the typical features of
      patients with recessive PD gene mutations including DJ-1.

- category: Neurologic
  name: Dystonia
  description: >-
    Dystonic posturing - classically lower-limb/foot dystonia, and often an
    onset feature - is relatively common in the autosomal recessive
    early-onset parkinsonisms including PARK-DJ1, and is a useful clinical
    pointer toward a monogenic recessive cause in a young patient.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: dystonia and dyskinesia being relatively common
    explanation: >-
      Systematic review of >1100 recessive PD patients (Parkin, PINK1, DJ1)
      reports dystonia as relatively common.
  - reference: PMID:22956510
    reference_title: "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EOPD mutation carriers were more likely to present with rigidity and
      dystonia
    explanation: >-
      Cohort evidence that recessive-gene mutation carriers present with
      dystonia more often than non-carriers. Marked PARTIAL because only
      7 mutation carriers were identified and none carried PARK7 variants.

- category: Neurologic
  name: Levodopa-Induced Dyskinesia
  description: >-
    Motor complications, in particular dyskinesia, develop relatively early
    in the recessive early-onset parkinsonisms - a consequence of young age
    at onset, a narrow therapeutic window, and prolonged pulsatile
    dopaminergic exposure.
  phenotype_term:
    preferred_term: Dyskinesia
    term:
      id: HP:0100660
      label: Dyskinesia
  evidence:
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: dystonia and dyskinesia being relatively common
    explanation: >-
      Systematic review reports dyskinesia as relatively common in the
      recessive early-onset forms including PARK-DJ1.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      PD patients with DJ-1 mutations exhibit an early onset of dyskinesia
    explanation: >-
      Specifically attributes early-onset dyskinesia to DJ-1 mutation
      carriers.

- category: Neurologic
  name: Hypomimia
  description: Reduced facial expression, part of the parkinsonian motor syndrome.
  phenotype_term:
    preferred_term: Hypomimic face
    term:
      id: HP:0000338
      label: Hypomimic face
  evidence:
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Parkinsonism associated with high-pitched voice and hypomimia
    explanation: >-
      Documents hypomimia in genetically confirmed PARK7 patients.

- category: Psychiatric
  name: Anxiety
  description: >-
    Psychiatric non-motor features, including anxiety, are a notable part of
    the PARK-DJ1 phenotype and typically follow the motor onset.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      followed by later manifestation of psychiatric symptoms, such as
      psychotic disturbance, anxiety, and cognitive decline
    explanation: >-
      Names anxiety among the psychiatric non-motor features of DJ-1
      mutation carriers.

- category: Psychiatric
  name: Psychotic Disturbance
  description: >-
    Psychotic symptoms are reported in DJ-1 mutation carriers, contributing
    to the high overall non-motor burden of this genotype.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      psychiatric symptoms, such as psychotic disturbance, anxiety, and
      cognitive decline
    explanation: >-
      Names psychotic disturbance among the psychiatric features of DJ-1
      mutation carriers.

- category: Neurologic
  name: Cognitive Decline
  description: >-
    Cognitive decline is reported in DJ-1 mutation carriers, although the
    MDSGene systematic review found cognitive decline to be relatively
    uncommon across the three recessive early-onset forms as a group - a
    discrepancy worth noting rather than smoothing over.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      psychiatric symptoms, such as psychotic disturbance, anxiety, and
      cognitive decline
    explanation: >-
      Names cognitive decline among the later features of DJ-1 mutation
      carriers.
  - reference: PMID:29644727
    reference_title: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: cognitive decline relatively uncommon
    explanation: >-
      Counterweight evidence: the pooled recessive-PD systematic review found
      cognitive decline relatively uncommon, tempering the review-level claim
      above.
  notes: >-
    Recorded here as an unresolved tension between a DJ-1-focused review and
    the pooled MDSGene data; a PARK7-only frequency band was deliberately not
    assigned.

- category: Neurologic
  name: High Non-Motor Symptom Burden
  description: >-
    Across the three autosomal recessive PD genes, DJ-1 mutation carriers
    carry the highest overall proportion of non-motor symptoms (57% in the
    MDSGene systematic review as summarised by Repici and Giorgini),
    suggesting that DJ-1 function is relevant beyond the nigrostriatal motor
    circuit.
  phenotype_term:
    preferred_term: Non-motor manifestations of parkinsonism (aggregate)
  frequency: FREQUENT
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      found that DJ-1 mutation carriers exhibit the highest percentage
      overall (57%) of non-motor symptoms
    explanation: >-
      Direct quantitative support for the FREQUENT band (57% falls in the
      HPO 30-79% range) and for the claim that DJ-1 carriers have the highest
      non-motor burden of the three recessive genotypes.
  notes: >-
    The frequency band is supported by the explicit 57% figure in the quoted
    sentence, per the frequency-evidence guidelines. No `term:` is bound
    deliberately: "non-motor symptoms" as an aggregate has no specific HPO
    class, and the only available ancestor (HP:0000707, Abnormality of the
    nervous system) is one step from the phenotypic-abnormality root and
    would convey nothing while polluting HPO-based exports. Prefer no term
    over a too-general one. The constituent features (anxiety, psychosis,
    cognitive impairment) are curated individually above with specific terms.

genetic:
- name: PARK7
  gene_term:
    preferred_term: PARK7
    term:
      id: hgnc:16369
      label: PARK7
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    PARK7 encodes DJ-1. Pathogenic variants act through loss of function and
    must be biallelic. The mutational spectrum spans large exonic deletions
    (requiring exon-dosage analysis in addition to sequencing), frameshift and
    nonsense variants, and destabilising missense substitutions such as L166P
    that lower steady-state protein levels and abolish homodimerisation.
    Because both point mutations and genomic rearrangements occur, sequencing
    alone is an inadequate screen. ClinGen's Parkinson's Disease Gene Curation
    Expert Panel classifies the PARK7-Parkinson disease relationship as
    Definitive with autosomal recessive inheritance.
  case_fractions:
  - population: Early-onset Parkinson disease, systematic review of published cohorts (>5800 unique cases)
    case_fraction_percent: 0.4
    notes: >-
      Weighted mean proportion of early-onset Parkinson disease cases carrying
      PARK7 (DJ-1) mutations, versus 8.6% for PARK2 (parkin) and 3.7% for
      PINK1 in the same analysis - PARK7 is by a wide margin the rarest of the
      three classic recessive EOPD genes.
    evidence:
    - reference: PMID:22956510
      reference_title: "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the weighted mean proportion of cases with PARK2 (parkin), PINK1, and
        PARK7 (DJ-1) mutations was 8.6%, 3.7%, and 0.4%, respectively
      explanation: >-
        Directly quantifies the PARK7 share of early-onset Parkinson disease
        cases in a systematic review of >5800 unique cases.
  - population: Sporadic early-onset Parkinson disease
    case_fraction_low: 1.0
    case_fraction_high: 2.0
    notes: >-
      Expert-review estimate for DJ-1 among sporadic early-onset cases,
      alongside 1-8% for PINK1; higher than the pooled systematic-review
      figure, reflecting different ascertainment.
    evidence:
    - reference: PMID:22166450
      reference_title: Autosomal recessive parkinsonism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Mutations in PINK1 and DJ-1 are less common, accounting for -1-8%, and
        -1-2% of the sporadic cases with early-onset.
      explanation: >-
        Provides the DJ-1-specific 1-2% share of sporadic early-onset cases.
  - population: Indian early-onset Parkinson disease cohort (100 probands)
    case_fraction_percent: 5.0
    cohort_size: 100
    notes: >-
      Higher share than Western cohorts, driven largely by the recurrent
      p.Arg98Gln variant. Interpretation caveat: rs71653619 (p.Arg98Gln) is a
      common polymorphism in some populations and its pathogenicity is
      debated, so this estimate should not be read as directly comparable to
      the systematic-review figure.
    evidence:
    - reference: PMID:27592010
      reference_title: "Early Onset Parkinson's disease due to DJ1 mutations: An Indian study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        DJ1 mutations account for ∼5% of EOPD patients from the Indian
      explanation: >-
        Cohort-specific case fraction from a 100-proband Indian EOPD series.
  evidence:
  - reference: CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z
    reference_title: "PARK7 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: >-
      ClinGen's Parkinson's Disease Gene Curation Expert Panel classifies the
      PARK7-Parkinson disease gene-disease relationship as Definitive with
      autosomal recessive inheritance.
  - reference: PMID:12446870
    reference_title: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The DJ-1 gene encodes a ubiquitous, highly conserved protein.
    explanation: >-
      Identifies the gene product and its ubiquitous, highly conserved
      character, which underpins the multi-system expression of DJ-1.
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since point mutations and genomic rearrangements can be present,
      sequencing and exon dosage are both required for accurate mutational
      screening of these genes.
    explanation: >-
      Supports the diagnostic-testing implication of the mutational spectrum:
      sequencing alone will miss the large deletions.
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A novel homozygous frameshift mutation in PARK7
    explanation: >-
      A worked example of a truncating PARK7 variant in the homozygous state
      causing the disease (NM_007262.4:c.90dupG, p.Ile31Aspfs*2).
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bi-allelic mutations in PARK7 are a rare cause of autosomal recessive
      early onset Parkinson's disease (EO-PD). To date, 30 individuals
      harbouring 20 unique causative variants have been described.
    explanation: >-
      Establishes the biallelic requirement and the small size of the
      reported variant/patient corpus as of 2019.

inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Disease requires biallelic PARK7 loss-of-function variants - homozygous
    (frequently in the setting of parental consanguinity or a founder
    haplotype) or compound heterozygous. Heterozygous carriers are generally
    unaffected, although heterozygous variants in the recessive PD genes have
    been reported in association with increased late-onset PD risk. The
    autosomal recessive mode is asserted independently by ClinGen's gene
    curation expert panel and by the founding genetic report.
  evidence:
  - reference: PMID:12446870
    reference_title: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in the DJ-1 gene associated with autosomal recessive
      early-onset parkinsonism.
    explanation: >-
      The founding report titles the entity as autosomal recessive
      early-onset parkinsonism.
  - reference: CGGV:assertion_d79439d2-844b-4ba6-aceb-e6b179eaaa01-2022-06-27T160000.000Z
    reference_title: "PARK7 / Parkinson disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PARK7 | HGNC:16369 | Parkinson disease | MONDO:0005180 | AR | Definitive"
    explanation: >-
      ClinGen records the mode of inheritance for the PARK7-Parkinson disease
      relationship as AR (autosomal recessive).
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Recessively inherited loss-of-function mutations in the parkin, DJ-1, or
      PINK1 gene are linked to familial cases of early-onset Parkinson's
      diseases (PD), and heterozygous mutations are associated with increased
      incidence of late-onset PD.
    explanation: >-
      Supports both the recessive mode and the reported heterozygote
      late-onset risk association. Marked PARTIAL because the heterozygote
      claim is a background statement, not a result of the cited study, and it
      pools the three recessive genes.

prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: ULTRA_RARE
  notes: >-
    No population prevalence estimate for PARK7-related early-onset Parkinson
    disease exists. The qualitative ULTRA_RARE band is assigned from the size
    of the reported patient corpus - 30 individuals with 20 unique causative
    variants described worldwide as of 2019 - rather than from a measured
    rate. No numeric rate_per_100000 is asserted, deliberately: converting a
    case count into a population rate would be fabrication. The gene-level
    share of early-onset Parkinson disease cases is curated as structured
    `case_fractions` on the PARK7 `genetic` record instead, which is the
    appropriate slot for a genetic-spectrum denominator. For the two-step
    rarity: early-onset Parkinson disease itself accounts for approximately
    3.6% of all Parkinson disease (PMID:22956510, "Approximately 3.6% of
    patients with Parkinson's disease develop symptoms before age 45"), and
    PARK7 explains only ~0.4% of that early-onset group. That 3.6% figure is
    a proportion of PD cases describing the PARENT population, not an
    occurrence measure for this disease, so it is recorded here as a note
    rather than as a second Prevalence record.
  evidence:
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bi-allelic mutations in PARK7 are a rare cause of autosomal recessive
      early onset Parkinson's disease (EO-PD). To date, 30 individuals
      harbouring 20 unique causative variants have been described.
    explanation: >-
      Establishes rarity and gives the reported-case count that grounds the
      ULTRA_RARE qualitative band.

treatments:
- name: Levodopa-Carbidopa
  description: >-
    Dopamine replacement with levodopa combined with the peripheral
    decarboxylase inhibitor carbidopa is the mainstay of treatment and works
    by restoring striatal dopaminergic transmission downstream of the lost
    nigrostriatal projection. PARK-DJ1 parkinsonism is characteristically and
    durably levodopa-responsive, documented over follow-up periods of six and
    fifteen years in a genetically confirmed family. Because onset is early
    and the disease course long, levodopa-induced dyskinesia is a common
    management problem in this population and argues for careful dose
    titration.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
    - preferred_term: carbidopa
      term:
        id: CHEBI:3395
        label: carbidopa
  target_mechanisms:
  - target: Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
    treatment_effect: MODULATES
    description: >-
      Exogenous levodopa is decarboxylated to dopamine in surviving terminals
      and other striatal cells, restoring dopaminergic tone to the basal
      ganglia motor circuit. It is purely symptomatic: it does not address the
      upstream DJ-1 loss, the oxidative stress, or the ongoing nigrostriatal
      degeneration.
  target_phenotypes:
  - preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The brothers were followed over a six and fifteen-year period and
      displayed typical levodopa responsive slowly-progressive Parkinsonism.
    explanation: >-
      Longitudinal human evidence for sustained levodopa responsiveness in
      genetically confirmed PARK7 disease.
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the phenotype is usually characterized by levodopa-responsive
      parkinsonism without atypical features
    explanation: >-
      Establishes levodopa responsiveness as the expected treatment response
      across the recessive early-onset forms including DJ-1 (PARK7).
  notes: >-
    Motor-complication caveat: dyskinesia is relatively common in the
    recessive early-onset parkinsonisms (see the Levodopa-Induced Dyskinesia
    phenotype), so levodopa dosing strategy matters more than in typical
    late-onset disease.

- name: Dopamine Agonist Therapy
  description: >-
    Non-ergot dopamine agonists such as pramipexole act directly on
    postsynaptic striatal dopamine receptors and are commonly used in
    early-onset Parkinson disease, often as initial therapy or as a
    levodopa-sparing adjunct intended to delay motor complications in patients
    facing decades of treatment. The mechanistic rationale is identical to
    levodopa's - replacing dopaminergic tone at the striatal node - but
    without requiring presynaptic conversion.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pramipexole
      term:
        id: CHEBI:8356
        label: pramipexole
  target_mechanisms:
  - target: Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
    treatment_effect: MODULATES
    description: >-
      Direct postsynaptic dopamine receptor agonism restores basal ganglia
      circuit signalling without depending on residual presynaptic dopamine
      synthesis capacity.
  evidence:
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the phenotype is usually characterized by levodopa-responsive
      parkinsonism without atypical features
    explanation: >-
      Indirect support only: the source establishes that the underlying
      deficit is a dopaminergic one that responds to dopamine replacement,
      which is the rationale for dopamine agonists, but it does not evaluate
      agonists specifically in PARK7 disease. Marked PARTIAL accordingly.
  notes: >-
    No PARK7-specific trial or cohort evidence for dopamine agonists exists;
    use here is extrapolated from general early-onset Parkinson disease
    management. Deliberately not asserted as PARK7-validated.

- name: Genetic Counseling
  description: >-
    Counselling for an autosomal recessive condition: recurrence risk for
    siblings of an affected proband is 25%, both parents are obligate
    carriers, and consanguinity is a common context. Counselling also covers
    the implications of the small and incompletely characterised PARK7
    patient corpus for prognostic advice, and carrier testing for at-risk
    relatives. The molecular testing strategy that establishes the diagnosis
    is curated separately under `diagnosis:`.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bi-allelic mutations in PARK7 are a rare cause of autosomal recessive
      early onset Parkinson's disease (EO-PD). To date, 30 individuals
      harbouring 20 unique causative variants have been described.
    explanation: >-
      Establishes the biallelic (autosomal recessive) transmission that
      determines the 25% sibling recurrence risk counselled here, and the
      small size of the reported corpus that limits prognostic counselling.

diagnosis:
- name: Molecular Genetic Testing (Sequencing plus Exon Dosage)
  description: >-
    Establishing a PARK7 diagnosis requires demonstrating biallelic
    pathogenic variants, and requires BOTH sequencing and exon-dosage
    (copy-number) analysis: the mutational spectrum includes large genomic
    rearrangements - the founding Dutch family carried a 14,082 bp deletion -
    that sequencing alone will miss, so a sequencing-only panel can return a
    false negative or report an apparently heterozygous carrier when the
    second allele is a deletion.
  evidence:
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since point mutations and genomic rearrangements can be present,
      sequencing and exon dosage are both required for accurate mutational
      screening of these genes.
    explanation: >-
      Directly specifies the two-pronged molecular testing strategy needed to
      make the diagnosis. Scope note: the source covers all three recessive
      genes (PARK2/PRKN, PINK1, PARK7) together.
- name: Clinical Selection of Patients for Recessive-Gene Testing
  description: >-
    Because PARK7 explains well under 1% of early-onset Parkinson disease,
    the clinical features that raise the pretest probability of a recessive
    monogenic cause matter more than for commoner genes: age at onset under
    40, an affected first-degree relative or sibling, and above all parental
    consanguinity, which raises the mutation yield to 50%. Mutation carriers
    are also more likely to present with rigidity and dystonia.
  evidence:
  - reference: PMID:22956510
    reference_title: "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations were more common in patients with age at onset (AAO) < 40
      (9.5%), an affected first-degree relative (6.9%), an affected sibling
      (28.6%), or parental consanguinity (50%).
    explanation: >-
      Quantifies the clinical features that should raise the pretest
      probability of a recessive monogenic cause and prompt testing. Scope
      note: the cohort covers PARK2/PRKN, PINK1, PARK7 and LRRK2 together.
- name: Documentation of Levodopa Responsiveness
  description: >-
    A sustained, unambiguous response to levodopa is a practical diagnostic
    discriminator that separates PARK-DJ1 from the atypical parkinsonian
    syndromes in the differential of a young patient with parkinsonism, and
    has been documented over six- and fifteen-year follow-up in a
    genetically confirmed PARK7 family.
  evidence:
  - reference: PMID:30928208
    reference_title: "Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The brothers were followed over a six and fifteen-year period and
      displayed typical levodopa responsive slowly-progressive Parkinsonism.
    explanation: >-
      Longitudinal documentation of the levodopa response that supports the
      clinical diagnosis in genetically confirmed PARK7 disease.
  - reference: PMID:22166450
    reference_title: Autosomal recessive parkinsonism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the phenotype is usually characterized by levodopa-responsive
      parkinsonism without atypical features
    explanation: >-
      Establishes absence of atypical features plus levodopa responsiveness
      as the expected diagnostic picture across the recessive early-onset
      forms including DJ-1 (PARK7).
  notes: >-
    Dopamine-transporter imaging (DaT SPECT) is the standard workup step that
    would confirm the presynaptic nigrostriatal deficit this entry's
    `Nigrostriatal Dopaminergic Neurodegeneration` node infers, but no
    PARK7-specific imaging series with a quotable result was found; it is
    deliberately not asserted here and is instead listed as a proposed
    experiment under the human/model-mismatch discussion.

discussions:
- discussion_id: park7_dj1_knockout_no_nigral_degeneration
  prompt: >-
    Why do DJ-1 knockout mice - and even parkin/DJ-1/PINK1 triple knockout
    mice aged to 24 months - fail to lose nigral dopaminergic neurons, when
    biallelic PARK7 loss reliably causes nigrostriatal degeneration in humans?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
  - pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
  rationale: >-
    This is the textbook translational mismatch of the recessive Parkinson
    disease genes. DJ-1 null mice reproduce dopaminergic FUNCTIONAL deficits -
    markedly reduced evoked striatal dopamine overflow, loss of corticostriatal
    long-term depression, open-field hypoactivity - but the substantia nigra
    dopaminergic neuron count is normal. Removing all three recessive PD gene
    products together does not rescue the model: triple knockouts still have
    normal nigral and locus coeruleus neuron numbers at 3, 16 and 24 months.
    The mismatch is mechanistically meaningful because it means that no
    existing rodent genetic model tests the step this entry most needs - the
    transition from cellular oxidative/bioenergetic stress to actual
    dopaminergic neuron death - and because it admits at least three distinct
    interpretations that current data do not separate: (a) mouse lifespan is
    simply too short for a slowly cumulative oxidative injury to reach the
    degeneration threshold; (b) DJ-1 is protective/modulatory rather than
    strictly required for nigral neuron survival, with the human phenotype
    requiring an additional insult or cumulative exposome that mice do not
    experience; or (c) species differences in dopaminergic neuron oxidant
    burden, neuromelanin (absent in mouse nigra), and antioxidant redundancy
    mean the mouse nigra is simply not the vulnerable cell population the
    human nigra is. Compounding this, the human end of the comparison is
    almost unconstrained: only ONE PARK7 patient brain has ever been examined
    neuropathologically. Any conclusion drawn from a negative mouse result
    should therefore be treated as uninformative about human PARK-DJ1 rather
    than as evidence against the mechanism.
  proposed_experiments:
  - experiment_id: exp_park7_multibrain_neuropathology
    name: Multi-brain neuropathological characterisation of PARK7 mutation carriers
    description: >-
      Coordinate international brain banks to obtain and systematically
      examine every available brain from a confirmed biallelic PARK7 carrier:
      stereological nigral dopaminergic cell counts, alpha-synuclein and Lewy
      body staging, and oxidative/carbonyl damage markers, benchmarked against
      age-matched idiopathic Parkinson disease and control brains. This is the
      only way to constrain the human end of the comparison, which currently
      rests on a single L172Q case.
    experiment_type:
      preferred_term: human post-mortem neuropathological case series
    readouts:
    - name: Nigral dopaminergic neuron loss
      target: pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
      direction: POSITIVE
    decision_criterion: >-
      Consistent stereological nigral dopaminergic cell loss across multiple
      PARK7 brains would confirm the human effector node and establish that
      the negative mouse result is a model limitation rather than evidence
      against the mechanism.
    would_support:
    - pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
  - experiment_id: exp_park7_ipsc_dopaminergic_ageing
    name: Aged patient-derived iPSC midbrain dopaminergic neurons and organoids
    description: >-
      Differentiate midbrain dopaminergic neurons and midbrain organoids from
      PARK7 null and L166P patient iPSCs alongside isogenic corrected
      controls, age them in culture, and challenge with sub-threshold
      oxidative and dicarbonyl stressors. Measure survival, mitochondrial
      function, and reactive oxygen species to test whether HUMAN dopaminergic
      neurons - unlike mouse - degenerate on DJ-1 loss.
    experiment_type:
      preferred_term: patient-derived iPSC neuronal model experiment
    perturbations:
    - name: Oxidative and dicarbonyl challenge of DJ-1-null human dopaminergic neurons
      target: pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
      description: >-
        Sub-threshold paraquat/hydrogen peroxide and methylglyoxal exposure of
        PARK7-null versus isogenic-corrected human midbrain dopaminergic
        neurons.
    readouts:
    - name: Dopaminergic neuron survival
      target: pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
      direction: POSITIVE
    decision_criterion: >-
      Selective death of PARK7-null human dopaminergic neurons under stress,
      rescued by isogenic correction, would show the stress-to-death step is
      human-permissive and mouse-refractory.
    would_support:
    - pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
  - experiment_id: exp_park7_longitudinal_dat_neuromelanin_imaging
    name: Longitudinal dopaminergic imaging in PARK7 biallelic carriers
    description: >-
      Serial dopamine-transporter SPECT/PET and neuromelanin-sensitive MRI in
      biallelic PARK7 carriers versus matched idiopathic early-onset Parkinson
      disease, to quantify the in vivo human rate of nigrostriatal loss - the
      benchmark any animal or cellular model must reproduce.
    experiment_type:
      preferred_term: longitudinal neuroimaging cohort study
    readouts:
    - name: Rate of striatal dopamine transporter signal decline
      target: pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
      direction: NEGATIVE
    decision_criterion: >-
      A measurable, progressive decline in nigrostriatal imaging markers in
      PARK7 carriers establishes the in vivo human degeneration rate against
      which the null mouse phenotype can be judged.
  - experiment_id: exp_park7_second_hit_dj1_null_mice
    name: Second-hit and long-lived-model designs in DJ-1 null animals
    description: >-
      Challenge DJ-1 null mice with sub-threshold oxidative or dicarbonyl
      stressors that do not cause degeneration in wild-type animals, and in
      parallel generate DJ-1 loss-of-function in a longer-lived or
      neuromelanin-bearing species, to discriminate the "mouse lifespan too
      short" interpretation from the "DJ-1 is protective but not required"
      interpretation.
    experiment_type:
      preferred_term: gene-environment interaction animal model experiment
    perturbations:
    - name: Sub-threshold oxidative or dicarbonyl second hit
      target: pathophysiology#Oxidative Stress and Mitochondrial Dysfunction in Nigral Dopaminergic Neurons
      description: >-
        Chronic low-dose paraquat, rotenone, or methylglyoxal exposure in DJ-1
        null versus wild-type animals.
    decision_criterion: >-
      Nigral degeneration emerging in DJ-1 null but not wild-type animals
      under a second hit would support the protective-not-required reading;
      degeneration emerging only with extended lifespan would support the
      lifespan reading.
  evidence:
  - reference: PMID:15721235
    reference_title: Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Although DJ-1(-/-) mice had normal numbers of dopaminergic neurons in
      the substantia nigra, evoked dopamine overflow in the striatum was
      markedly reduced, primarily as a result of increased reuptake.
    explanation: >-
      The canonical demonstration that DJ-1 null mice reproduce dopaminergic
      dysfunction without nigral cell loss.
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we found that triple knockout mice lacking Parkin, DJ-1, and PINK1 have
      normal morphology and numbers of dopaminergic and noradrenergic neurons
      in the substantia nigra and locus coeruleus, respectively, at the ages
      of 3, 16, and 24 months.
    explanation: >-
      Shows that combined inactivation of all three recessive PD genes still
      fails to produce nigral degeneration within the mouse lifespan.
  - reference: PMID:19694908
    reference_title: Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      suggesting that these genes may be protective rather than essential for
      the survival of dopaminergic neurons during the aging process
    explanation: >-
      The authors' own preferred interpretation, curated here as one of the
      competing readings of the mismatch.
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      DJ-1 gene knockout mice, despite exhibiting a normal number of
      dopaminergic neurons in the substantia nigra, show subtle neurochemical
      and behavioral abnormalities
    explanation: >-
      Review-level confirmation that the mouse model captures neurochemistry
      and behaviour but not neurodegeneration.

- discussion_id: park7_glyoxalase_versus_deglycase_controversy
  prompt: >-
    Is DJ-1's catalytic activity toward reactive dicarbonyls a
    glutathione-independent glyoxalase activity on free methylglyoxal, a
    protein deglycase activity repairing already-formed glycation adducts, or
    neither in vivo - and does dicarbonyl stress contribute materially to
    human PARK-DJ1 neurodegeneration?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
  rationale: >-
    This is a genuine, unresolved scientific disagreement, not a curation
    ambiguity, and it is curated as a controversy rather than asserted in
    either direction. The glyoxalase claim (DJ-1 converts free glyoxal and
    methylglyoxal to glycolate and lactate without glutathione) and the
    deglycase claim (DJ-1 repairs methylglyoxal- and glyoxal-glycated
    cysteine, arginine and lysine residues on proteins) were published as
    competing biochemical accounts of the same protein. The deglycase claim
    was then directly challenged twice: a Drosophila study detected no
    contribution of DJ-1 to methylglyoxal survival or adduct accumulation in
    vivo and ascribed the reported deglycation to a TRIS buffer artifact,
    prompting published rebuttal correspondence in the same journal; and an
    independent kinetic analysis showed that the fast equilibrium between
    free methylglyoxal and hemithioacetals (equilibrium constant ~500 per
    molar, hemithioacetal half-life 12 s) means that glyoxalase-mediated
    removal of free methylglyoxal forces spontaneous hemithioacetal
    decomposition that can be mistaken for deglycase activity. That second
    study concluded that DJ-1 does not possess protein deglycase activity -
    but ALSO found that DJ-1-knockout human cells were not sensitised to
    acute methylglyoxal toxicity, so it does not rescue the glyoxalase arm as
    a disease-relevant protective mechanism either. The practical consequence
    for this entry is that the dicarbonyl node and its downstream edge are
    scoped to hypothesis groups rather than folded into the canonical chain,
    and no PARK-DJ1 clinical or therapeutic claim is made on the basis of
    dicarbonyl biology.
  proposed_experiments:
  - experiment_id: exp_park7_human_age_quantification
    name: Quantification of methylglyoxal-derived AGEs in PARK7 patient tissue
    description: >-
      Measure methylglyoxal-derived advanced glycation end-products (MG-H1,
      argpyrimidine, carboxyethyl-lysine) by mass spectrometry in substantia
      nigra tissue and CSF from biallelic PARK7 carriers versus idiopathic
      Parkinson disease and controls, to test whether dicarbonyl stress is
      actually elevated in the human disease rather than only in reconstituted
      systems.
    experiment_type:
      preferred_term: targeted mass spectrometry biomarker study
    readouts:
    - name: Methylglyoxal-derived advanced glycation end-product burden
      target: pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
      direction: POSITIVE
    decision_criterion: >-
      Elevated MG-derived AGEs in PARK7 nigra/CSF relative to controls would
      promote the dicarbonyl node from hypothesis-scoped to canonical; no
      elevation would justify demoting it.
    would_support:
    - pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
  - experiment_id: exp_park7_separation_of_function_alleles
    name: Separation-of-function DJ-1 alleles in human dopaminergic neurons
    description: >-
      Design structure-guided DJ-1 alleles that ablate glyoxalase activity
      while preserving Cys106 redox sensing and NRF2 stabilisation, and
      conversely, and express each in PARK7-null patient-derived iPSC
      dopaminergic neurons to determine which activity is required for
      dopaminergic neuron survival under stress.
    experiment_type:
      preferred_term: structure-guided separation-of-function rescue experiment
    perturbations:
    - name: Activity-selective DJ-1 rescue alleles
      target: pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
      description: >-
        Re-expression of glyoxalase-dead but redox-competent DJ-1, and
        redox-dead but glyoxalase-competent DJ-1, in PARK7-null human
        dopaminergic neurons.
    decision_criterion: >-
      If only the redox-competent allele rescues survival, the dicarbonyl arm
      is dispensable for the disease mechanism; if the glyoxalase-competent
      allele also rescues, dicarbonyl detoxification is disease-relevant.
    would_refute:
    - pathophysiology#Loss of DJ-1 Dicarbonyl Detoxification Capacity
  - experiment_id: exp_park7_buffer_controlled_kinetics_replication
    name: Multi-laboratory buffer-controlled replication of DJ-1 enzyme kinetics
    description: >-
      Standardised, TRIS-free, buffer-controlled re-measurement of DJ-1
      glyoxalase and deglycase kinetics across independent laboratories using
      shared protein preparations and substrates, since a buffer artifact is
      one of the explicit competing explanations for the discrepant results.
    experiment_type:
      preferred_term: multi-laboratory enzyme kinetics replication study
    decision_criterion: >-
      Reproducible deglycase activity under TRIS-free conditions across
      laboratories would restore the deglycase hypothesis; its absence would
      settle the controversy in favour of glyoxalase-only activity.
  evidence:
  - reference: PMID:22523093
    reference_title: Human DJ-1 and its homologs are novel glyoxalases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Purified DJ-1 proteins exhibit typical Michaelis-Menten kinetics, which
      were abolished completely in the mutants of essential catalytic
      residues, consisting of cysteine and glutamic acid.
    explanation: Enzymological support for the glyoxalase side of the controversy.
  - reference: PMID:25416785
    reference_title: "Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These results suggest that DJ-1-associated Parkinsonism results from
      excessive protein glycation and establishes DJ-1 as a major
      anti-glycation and anti-aging protein.
    explanation: >-
      The deglycase side of the controversy, stated as an explicit pathogenic
      model for PARK-DJ1.
  - reference: PMID:27903648
    reference_title: Evidence Against a Role for the Parkinsonism-associated Protein DJ-1 in Methylglyoxal Detoxification.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we could detect no contribution of DJ-1 to survival to MG challenge or
      to accumulation of MG protein adducts
    explanation: >-
      In vivo refutation of any DJ-1 contribution to methylglyoxal handling.
  - reference: PMID:31653696
    reference_title: The apparent deglycase activity of DJ-1 results from the conversion of free methylglyoxal present in fast equilibrium with hemithioacetals and hemiaminals.
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: >-
      Experiments with CRISPR/Cas-generated DJ-1-knockout HEK293 cells
      revealed that DJ-1 does not protect against acute MGO toxicity or
      carboxymethylation of lysine residues in cells.
    explanation: >-
      Human-cell knockout data arguing against a protective dicarbonyl role
      for DJ-1 under either enzymological account.

- discussion_id: park7_synucleinopathy_status_unknown
  prompt: >-
    Is PARK7-related early-onset Parkinson disease a synucleinopathy? Only a
    single mutation-carrier brain has been examined, and it showed Lewy body
    pathology.
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
  rationale: >-
    The `Parkinson's Disease` entry models alpha-synuclein aggregation and
    Lewy pathology as a central mechanism, and the shared
    parkinsonism_dopaminergic_degeneration module carries an alpha-synuclein
    arm that conforming disorders may include or omit. This entry deliberately
    OMITS that arm, because the evidence to include it does not exist: exactly
    one DJ-1-mutation brain (L172Q) has been analysed neuropathologically. It
    did show Lewy bodies, which is suggestive but is a single observation.
    Cell-biological work independently shows that DJ-1 acts as a
    redox-dependent chaperone whose activity extends to alpha-synuclein,
    giving a plausible mechanistic route from DJ-1 loss to alpha-synuclein
    aggregation - but plausibility from in vitro chaperone assays plus one
    autopsy is not a basis for asserting a synucleinopathy node in the
    pathograph. Resolving this determines whether PARK-DJ1 should declare
    conformance to the module's alpha-synuclein node and whether
    synuclein-directed therapies are mechanistically rational here.
  proposed_experiments:
  - experiment_id: exp_park7_synuclein_neuropathology_survey
    name: Systematic alpha-synuclein neuropathology survey of PARK7 brains
    description: >-
      Via international brain-bank coordination, apply alpha-synuclein
      immunohistochemistry, Lewy body staging, and oxidised-DJ-1 staining to
      every obtainable brain from a biallelic PARK7 carrier, to determine
      whether Lewy pathology is a consistent feature or an isolated finding in
      the single reported L172Q case.
    experiment_type:
      preferred_term: human post-mortem immunohistochemistry survey
    readouts:
    - name: Alpha-synuclein Lewy pathology burden
      target: pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
      direction: POSITIVE
    decision_criterion: >-
      Consistent Lewy pathology across multiple PARK7 brains would justify
      adding an alpha-synuclein node and declaring conformance to the module's
      alpha-synuclein arm; its absence would confirm the current omission.
  - experiment_id: exp_park7_synuclein_seed_amplification
    name: Alpha-synuclein seed amplification assay in living PARK7 carriers
    description: >-
      Perform alpha-synuclein seed amplification (RT-QuIC) on CSF and skin
      biopsy from living biallelic PARK7 carriers, which can establish
      synucleinopathy status in vivo without waiting for autopsy material and
      can be repeated longitudinally.
    experiment_type:
      preferred_term: seed amplification assay biomarker study
    readouts:
    - name: CSF and skin alpha-synuclein seeding activity
      target: pathophysiology#Nigrostriatal Dopaminergic Neurodegeneration
      direction: POSITIVE
    decision_criterion: >-
      Positive seeding activity in a majority of PARK7 carriers would classify
      PARK-DJ1 as a synucleinopathy in vivo; consistently negative assays
      would establish it as a non-synuclein dopaminergic degeneration.
  evidence:
  - reference: PMID:31484320
    reference_title: "DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      very little is known regarding the neuropathology in brains from
      patients carrying DJ-1 mutations
    explanation: >-
      States the gap directly: the neuropathology of PARK-DJ1 is essentially
      uncharacterised.
  - reference: PMID:15502874
    reference_title: DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: >-
      We further demonstrate that DJ-1 chaperone activity in vivo extends to
      alpha-synuclein, a protein implicated in PD pathogenesis.
    explanation: >-
      Provides the mechanistic plausibility for a synuclein link. Marked
      INDIRECT because chaperone activity in a cellular system does not
      establish that human PARK-DJ1 brains accumulate alpha-synuclein.
📚

References & Deep Research

References

3
PMID:20301402
Monogenic Parkinson Disease Overview
No top-level findings curated for this source.
PMID:31484320
DJ-1 in Parkinson's Disease: Clinical Insights and Therapeutic Perspectives
No top-level findings curated for this source.
PMID:29644727
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review
No top-level findings curated for this source.